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ABSTRACT
BIOCHEMISTRY OF HEMOLYSIN TOXIN ACTIVATION BY FATTY
ACYLATION: CHARACTERIZATION OF AN INTERNAL
PROTEIN ACYLTRANSFERASE
by
Michael Stephen Trent
Hemolysin toxin produced and secreted by pathogenic Escherichia coli is one of a family
of cytolytic, structurally homologous protein toxins known as RTX (repeats in toxin)
toxins. RTX toxins are products of a gene cluster, CABD. The A gene product, nontoxic
hemolysin (proHlyA) is made toxic by post-translational fatty acylation of two internal
lysine residues. HlyC, C gene product, is essential for acylation, and acyl-acyl carrier
protein (ACP) is the acyl donor. HlyB and HlyD are involved in secretion of the toxin.
HlyC was thought to serve as an internal protein acyltransferase and remained
uncharacterized until now.
ProHlyA and HlyC were separately subcloned, expressed, and purified, and acyl-ACPs
with diverse radioactive acyl groups were synthesized. With these proteins, the
conversion of proHlyA to HlyA by acyltransfer was assayed. Acyl-ACP was the obligate
acyl donor. Acyltransfer was catalyzed by HlyC monomer, and an acyl-enzyme
intermediate was detected and shown to catalyze the reverse reaction. The reaction
mechanism was examined by steady state kinetics, and the nature of inhibitions by
reaction products was determined. The kinetic mechanism of the internal protein
acylation was compatible with an uni uni iso uni uni ping pong with isomerization of the
F form of the enzyme.

Clues to the chemical mechanism for the acyltransferase were elucidated by both
chemical modification studies and site directed mutagenesis of the enzyme. Chemical
modification experiments ruled out any critical cysteines, serines, and lysine residues, but
suggested a role for histidine(s) and tyrosine(s) in acyltransferase function. In order to
iii
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examine the function of specific residues and possibly corroborate the chemical findings,
site directed mutagenesis studies of the acyltransferase were empolyed. Seventeen
residues that were conserved among 13 different RTX toxin acyltransferases were
individually mutated, and the respective HlyCs expressed, and characterized. Residues
that were critical for acyltransferase function included Gly 11, His 23, Tyr 70, and Gly
85. As with chemical modification data, mutagenesis ruled out any conserved, essential,
cysteines or serines critical for HlyC acyltransferase activity.
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CHAPTER 1
INTRODUCTION

Pathogenic Escherichia coli secrete a toxic protein, hemolysin (HlyA), which
binds to and lyses mammalian cell membranes and, at lower concentrations, perturbs cell
signal transduction and release of inflammatory mediators. Approximately 50% o ff.
co li causing extraintestinal infections in man produce HlyA, thus it is considered an
important virulence factor ( I, 2). It is a member of a family o f homologous cytolytic
toxins produced by Gram negative bacteria. These newly discovered toxins are
characterized by the presence of numerous glycine rich nine amino acid repeat units and
have been labeled the RTX (repeat in toxin) toxins (3). In addition to their unique
structural feature, the toxins share a Ca2+dependency for cell lysis, a signal-peptide
independent secretion mechanism, a common mode of activation, but they vary in target
cell specificity. Various RTX toxins include: enterohemorrhagic 0157:H7 £. coli
hemolysin (EhxA) (4), Bordetella pertussis bifunctional adenylate cyclase-hemolysin
(CyaA), Pasteurella hemolytica leukotoxin (LktA), Actinobacillus
actinomycetemcomitans leukotoxin (AaltAy), and Actinobacillus pleuropneumoniae
hemolysins (ApxIA and ApxIIA) and leukotoxin (ApxIHA), with E. coli HlyA
considered the prototype of the group (5).
The E. coli HlyA toxin arises from the expression of the hlyCABD operon located
on either the bacterial chromosome or conjugative plasmids (d). The hlyA gene product
is first synthesized as a 110 kDa inactive protoxin (proHlyA) that is post translationally
modified by the hlyC gene product, HlyC (7). The acylation reaction occurs within the
cytosol of the bacterium and requires HlyC for the transfer of a fatty-acyl group from
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acyl-acyl earner protein (acyl-ACP) to proHlyA, converting it to HlyA. Acyl-ACP is

2

the obligate acyl donor with acyl-CoAs not serving as substrates in the reaction (8). Like
acyl-CoA, the acyl group of acyl-ACP is attached to the protein via a thioester bond on
the terminal sulfhydryl o f a 4’-phosphopantethiene group that is attached to ACP via a
phosphodiester bond to serine 36 (9). Acyl-ACP is a small (~9 kDa), acidic protein that
was first discovered to function in the fatty acid biosynthetic pathways (9). Since then,
acyl-ACP has been shown to function as an acyl donor in the synthesis o f phospholipids
(70), lipid A component of lipopolysaccharide (LPS) (77), membrane-derived
oligosaccharides (72), and for the synthesis of lipoylated enzymes as lipoyl-ACP (73).
After acylation, HlyA is secreted from the bacterium by the action of two specific inner
membrane proteins, HlyB and HlyD, which are part o f the hemolysin operon, and the
outer membrane protein, TolC (14,15). Acylation is not essential for secretion (7), but
acylation is the single factor that renders the protein toxic.
Although, the exact role of HlyC was not known when the present study began, it
was assumed to function as an acyltransferase. The nature of in vitro HlyC-dependent
modification of proHlyA was shown to be an internal acylation of the e-amino groups of
lysine residues 564 and 690 forming amide bonds (76). The in vivo acylation pattern of £.
coli hemolysin was shown to be the same as the in vitro activated toxin (77), but the
nature of the fatty acid in vivo remains unknown. The in vivo modification of CyaA, the
adenylate cyclase toxin from Bordetella pertussis, was shown to be palmitoylation of the
e-amino group of a single internal residue, lysine 983, corresponding to lysine 690 of
HlyA (18). A summary of the HlyC-dependent HlyA activation by fatty acylation is
shown in Figure I.
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proHlyA

Figure 1: E. coli hemolysin (HlyA) acylation and secretion. (CM, cytoplasmic
membrane; OM, outer membrane) HlyA is expressed first as the inactive protoxin,
proHlyA, which is activated by fatty acylation by the acyltransferase HlyC. Acyl-ACP
serves as the acyl donor. HlyA is secreted through a sec-independent pathway by the two
gene products o f the hemolysin operon, hlyB and hlyD, and one unrelated protein tolC.
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Once acylated and in the presence o f Ca2\ HlyA has the ability to bind and form
cation-specific channels in target cells leading to osmotic lysis (79). The nature o f cell
lysis is not yet fully understood, and the finer points of the subject will not be discussed
here. It seems to occur via a two-step mechanism: a reversible membrane adsorption step
followed by an irreversible insertion (20), the latter requiring a change in HlyA
conformation (27). It is assumed that membrane insertion is followed by toxin
oligomerization within the host cell membrane leading to pore formation (22, 23).
HlyA is a powerful lytic agent, but also of great interest are host cell responses
elicited at subhemolytic doses. For example, HlyA induces leukotriene production and
phosphoinositide hydrolysis in human neutrophils (7), stimulates nitric oxide production
in porcine endothelial cells (24), increases production of interleukin (IL )l-(i and tumor
necrosis factor (TNF) in human monocytes (2); and induces the rapid and massive
shedding of the LPS (CD 14) and the IL-6 receptors (25). In addition to these responses,
HlyA and other RTX toxins have been shown to induce apotosis in human lymphocytes
(26, 27).
The various RTX toxins differ in cell and host specificity and are divided into two
groups, hemolysins and leukotoxins. For example, HlyA and the hemolysins ApxIA and
ApxEA, have a wide range of specificity including erythrocytes and leukocytes o f
animals and humans; whereas, the LktA and AaltA leukotoxins have no effect on
erythrocytes, but are powerful toxins for a narrow range of phagocytic cells of ruminants
and humans, respectively (28). The differences in target cell sensitivity for the R TX
toxins could be attributed to several reasons including target cell receptor recognition,
membrane composition, and membrane repair mechanisms. Recently, Lally and
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colleagues showed evidence that the AaltA leukotoxin and HlyA bind to the CD1 la-

5

CD18 integrin (lymphocyte function-associated antigen 1) on human cells, possibly
functioning as a receptor (29).
HlyA toxicity is Ca2* dependent with the RTX toxin nonapeptide repeat unit
(Leu-X-Gly-Gly-X-Gly-(Asn/Asp)-Asp-X) functioning as a Ca2*-binding motif via the
negatively charged aspartate residues (30, 31). HlyA contains 11-17 repeat units,
depending upon how much one adheres to the consensus sequence, between amino acids
739 and 849 (32). Ca2+ binding is not dependent upon HlyC modification and the
necessity of Ca2" for HlyA activity is not fully understood. Although Ca2+ binding has
not been shown to induce a large conformational change in HlyA, there are associated
changes in surface hydrophobicity in the Ca2" bound state (33) and Ca2~ induced
conformational changes have been shown for CyaA (34, 35).
The hemolysin system provides a unique opportunity to study an internal
acylation of a protein. Internal fatty acylation of proteins is recognized as a means of
modifying protein behavior in biological regulatory mechanisms such as signaling, and
many toxins exert their effects through distortion of cellular signaling mechanisms.
Numerous instances o f eukaryotic protein fatty acylation have been reported (36) and two
classes of acylproteins are found in the literature. One is typified by 14 carbon myristic
acid in an amide-linkage to the N-terminal glycine of the target protein following
removal o f the initiator methionine. The reaction is catalyzed by the ubiquitous
myristoyl-CoA: protein N-myristoyl transferase and has been thoroughly characterized
(37). The second group contains primarily hexa- or octadecanoic acids in ester linkages
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with internal cysteine or threonine residues, and with less frequency in an amide linkage
to lysine residues (38, 39).
The acyltransferases catalyzing these internal acylations have been elusive and
remain for the most part uncharacterized; although, recently two protein palmitoyl
acyltransferases that transfer palmitoyl groups to H-Ras and spectrin have been purified
(40, 41). Palmitoylation of proteins at the thiol group of cysteine residues results in
thioester bonds which are labile in nature, and a thioesterase that removes palmitate from
H-Ras and Ga subunits has been cloned (42). Unlike a thiol ester, the amide linkage of
acyl groups results in a stable lipid modification. HlyA and other members of the RTX
toxin family are the only known prokaryotic proteins that are post-translationally
modified by internal amide fatty acylation. There are four eukaryotic proteins that are
known to have internal acylated lysine residues: TNF-a (43), IL -la , IL -ip (44), and
cytochrome c oxidase (45). Also, two integral membrane proteins, nicotinic
acetylcholine receptor and the insulin receptor, are speculated to contain an internal
amide linked fatty acid, but the sites of acylation are unkown (46, 47). In time, more
internal amide-linked fatty acylations will emerge since metabolic labeling studies predict
that only a fraction o f acylproteins have been identified (48). None of the
acyltransferases catalyzing internal amide acylations have been cloned, isolated, or
characterized, leaving the characterization of HlyC a unique opportunity.
Comparison o f the HlyC sequence to known acyltransferases via a BLAST search
revealed no similarities and it has been reported that proHlyA and HlyC are produced in
almost equimolar amounts (49), confusing the issue that HlyC functions as a catalyst.
However, the common scheme o f the RTX activation/acylation reaction is demonstrated
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by the fact that RTX C gene products can activate RTX toxins from different organisms,
suggesting that the RTX acyitransferases function in a similar fashion. For example, the
hemolysin of Actinobacillus pleuropneumoniae (ApxIA), the Pasteurella hemolytica
leukotoxin (LktA), and the Bordetella pertussis adenylate cyclase toxin (CyaA) have all
been activated by the E. coli HlyC acyltransferase (5 0,51, 52,53). An indirect,
unstandardized assay o f undefined stoichimetry has been used previously to monitor the
function of the putative enzyme. Routinely, proHly A activated by HlyC was incubated
with a suspension o f erythrocytes in the presence of Ca2\ and the amount of hemoglobin
released was monitored. Since the mechanism of hemolysis is unknown, the amount of
proHlyA acylated cannot be determined by this method, and the two separate events,
acylation and lysis cannot be measured independently.
The role of HlyC in acylation of proHlyA needed clarification. To address the
issue of HlyC’s putative acyltransferase function, HlyC and proHlyA were subcloned into
separate hyperexpression systems and purifed. Using purified, defined acyl-ACP (with
radioactive acyl groups) and proHlyA, the acyltransferase activity o f HlyC was studied,
and the enzyme characterized. The reaction under investigation is shown below.

proHlyA + [14C]acyl-ACP

[,4C]HlyA + ACPSH

Such an assay enabled independent study of two significant and separate events, internal
acylation of a protein and characterization of a toxin. The enzyme was fully
characterized and evidence that HlyC functions as an acyltransferase is presented.
Because Ca2+ is required for toxin function, the effects o f Ca2+ on HlyA acylation were
studied. The kinetic parameters of acyl-ACPs bearing diverse acyl groups were
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determined as well as the toxicities of the acyl-toxins they produced. Notably, HlyC
formed a reactive acyl-enzyme intermediate, and the acyl-HIyC intermediate was able to
catalyze the reverse reaction transferring the acyl group to ACPSH forming acyl-ACP.
The kinetic or chemical mechanism o f an enzyme catalyzing the internal acylation
of a protein has never been determined. In the present study, the kinetic mechanism of
the internal acylation of proHlyA catalyzed by HlyC was determined by steady state
kinetics and by reaction product inhibition studies. Finally, chemical modification and
site-directed mutagenesis o f HlyC were used as tools to determine residues involved in
the catalysis of the acyl transfer reaction contributing to the delineation of the chemical
mechanism.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

CHAPTER 2
MATERIALS AND METHODS

Biolpgicals and Reagents
[ l - ,4C]labeled fatty acids, [1-I4C] palmitoyl-CoA, and [ l - 14C]sodium pantothenate
were from New England Nuclear except for lauric acid which was from Amersham.
American Radiolabeled Chemicals, Inc. supplied [9,10-3H] labeled palmitoleic acid.
Palmitoyl-CoA was from P.L. Biochemicals. Novagen was the source of alkaline
phosphatase conjugated S-peptide. Nitrocellulose, 0.4S pM, was from Costar. Spectrum
Medical Industries, Inc. was the source of Spectra/Gel A4. Agar for DNA electrophoresis
was from FMC. The following items were supplied by Fisher Scientific: 40% stock
acrylamide:bisacrylamide (37.5:1) solution, hydroxylamine (NH2OH), dithiothreitol
(DTT), isopropyl thiogalactoside (IPTG), sodium dodecyl sulfate (SDS), sodium
deoxycholate, urea, chloramphenicol, kanamycin, tetracycline, ampicillin, bovine serum
albumin, Spectra/Por dialysis tubing, bacto-tryptone, bacto-yeast extract and agar. Nethylmaleimide (NEM ), /7-chloromercuribenzoate (PCMB), phenylmethylsulfonyl fluoride
(PMSF), 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF), diethylpyrocarbonate
(DEPC), tetranitromethane (TNM), phenylglyoxal (PG), thrombin, ribonuclease S-protein.
Kodak film, dimethyl suberimidate, Coomassie brilliant blue R, and Tween-20 were from
Sigma. EcoKV, deoxynucleotides, ammonium persulfate, 5-bromo-4-chloro-3-indoyl
phosphate (BCIP), nitrobiue tetrazolium (NBT), N, N, N \ N',-tetramethylethylenediamine
(TEMED), Wizard DNA Clean-Up System, Wizard Miniprep and Midiprep DNA
Purification System were from Promega. New England Biolabs was the source of T4
9
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DNA ligase, calf intestinal phosphatase, Deep Vent DNA polymerase, Deep Vent 10X
buffer, and Dpn I. Pfu Turbo DNA polymerase and XL-2 Blue Ultracompetent cells were
from Stratagene. Protein molecular weight standards were from Bio-Rad, Novex, and
New England Biolabs. High and low DNA mass standards were from Life Technologies.
All chemicals were reagent grade.

Escherichia coli
Novagen was the source of E. coli strains HMS174, BLR(DE3),
BLR(DE3)pLysS, BL21(DE3)pLysS, and NovaBlue cells. Permanent stocks of E. coli
were stored at -80 °C as 8% glycerol stocks. The genotype of each strain is listed in
Table 1. E. coli cultures were routinely grown in Luria broth (LB) (54) at 37 °C at 200
rpm. Other bacterial growth media included M9 minimal media (54), 2XTY and TB
medium (55). LB-agar plates were prepared by the addition of 20 g agar per liter LB
medium. Growth media were supplemented with either kanamycin, tetracycline,
chloramphenicol, or ampicillin with final concentrations of 34 pg/mL, 12.5 pg/mL, 34
pg/mL and 50 pg/mL respectively.

Recombinant DNAs and Techniques
Preparation of Competent E. coli Cells
All bacterial strains used for the introduction of plasmid DNA were made
competent by the calcium chloride method of transformation (56), except for the XL-2
Blue strain which was purchased from Stratagene.
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Table I. E C O U STRAIN GENOTYPE DESCRIPTIONS
Strain

Genotype

HMS174

F recA hsdR (nci2*mKi2~) Rif*

BLR(DE3)

F ompT hsdSe (rs'ma*) gal dcm A(srl-recA)306::Tnl0 (Tc*) A.
(DE3)
F ompT hsdSa (rs'ma') gal dcm A(srl-recA)306. Tn 10 (Tc*) X
(DE3) pLysS (Cmr)
F ompT hsdSB (ra'ma*) gal dcm X(DE3) pLysS (Cm1)

BLR(DE3)pLysS
BL21(DE3 )pLysS
XL-2 Blue strain
NovaBlue

recAl endAl gyrA96 thi-1 hsdR17 supE44 relAl lac [F proAB
laclqZAM15 TnlO (Tet1) Amy Cam*]*
endAl hsdR17 (rKn'mKu ) supE44 thi-1 recAl gyrA96 relAl
lacfF proA*B* laclqZAM15::TnlO (Tc^l

Transformation
The method for the introduction of plasmid DNA into E. coli host, except for the
XL-2 Blue strain, was that outlined by the pET System Manual from Novagen (55). The
method of transformation of XL-2 Blue E coli was that outlined by the Epicurian Coli
Ultracompetent and Supercompetent Instruction Manual from Stratagene. XL-2 Blue E.
co li were only used for transforming PCR products prepared for the construction of
mutant hfyCs.

Plasmid Purification
Plasmids containing the native HlyC or mutant hlyC genes were propagated in
NovaBlue and XL-2 Blue E. coli strains respectively. The Wizard Miniprep and Midiprep
DNA purification systems were used for the small-scale and large-scale isolations o f
plasmid respectively. These systems were used only when the resulting plasmid
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preparation was needed as template for DNA sequencing reactions, template for sitedirected mutagenesis, or during vector preparation for subcloning. Isolation o f plasmid
DNAs from positive clones during subcloning of hemolysin genes were performed
following a method outlined by the pET system manual from Novagen (55).

DNA Agarose Gel Electrophoresis
DNA electrophoresis was carried out using the Minicell EC370 electrophoretic gel
system from Fisher Scientific. For routine analysis of DNA samples, samples were run on
40 mM Tris-acetate, 1 mM EDTA (TAE) agarose gels and stained during electrophoresis
by including ethidium bromide in the TAE electrophoresis buffer at 0.33 pg/mL. DNA
samples were mixed with S0% glycerol solution containing 0.25% w/v bromophenol blue
prior to application to the gel. Electrophoresis was routinely performed at 100 V and
monitored by movement of the bromophenol blue. Excess ethidium bromide was removed
by destaining in water for 20 minutes. The presence of DNA was visualized by U Vtransillumination on a 312 nm variable intensity transilluminator. For preparation o f DNA
to be isolated from agarose gel slices for subsequent applications, no ethidium bromide
was included in either the agarose gel or the electrophoresis buffer. To locate DNA to be
isolated from the gel, an additional lane containing a duplicate sample was separated from
the rest of the gel and stained for 20 min in TAE buffer containing ethidium bromide as
described above.
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DNA Quantification
DNA was quantified by comparison to either low DNA (100 bp - 2000 bp) mass
or high DNA (1000 bp -10,000 bp) mass standards electrophoresed along with samples of
unknown concentrations.

Genetic Materials
Novagen was the source of pET plasmids. Dr. Colin Hughes provided the
construct pEKSO (57) containing the MyCABD operon used to produce native (flyA.
Both pTXA l and pTXCl were prepared by Dr. Lesa Worsham in this laboratory and
served as separate hyperexpression systems for proHlyA and S-tag-HlyC respectively
(58).

Oligonucelotides
Oligonucleotides used for subcloning of the native hlyC gene, site-directed
mutagenesis o f hlyC, or for colony screening were purchased from Integrated DNA
Technologies and are described in Table 2.

Construction o f Recombinant His^-S-taa-HlvC
HlyC was expressed as a His«-S-tag fusion protein using pET30(a)+ and a 513 bp
PCR product from pEKSO encoding HlyC. pET30a(+) vector treated with the restriction
endonuclease £coRV, followed by treatment with calf intestinal phosphatase, was
separated from remaining undigested pET30a(+) using a 0.7% agarose gel. Gel slices
containing the digested vector were removed and the DNA isolated using a spin column.
Vector was concentrated by precipitation with ethanol and sodium acetate (55,59). The
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Table 2: OLIGONULCEOTIDES
>\b
Name*
Sequence (S’ to 3’)
HlyC Upper
ATGAATATAAACAAACCATTAGAGATTCTT
TTAACCAGTTAATGAAAAATTAAAATCTGA
HlyC Lower
T7 Promoter
TAATACGACTCACTATAGGG
GUA Upper
CCATTAGAGATTCTTGCTCATGTATCCTGGCTATGGGCCAG
G11A Lower
CTGGCCCATAGCCAGGATACATGAGCAAGAATCTCTAATGG
S20A Upper
CCTGGCTATGGGCCAGTGCTCCACTACACAGAAACTGGCC
S20A Lower
GGCCAGTTTCTGTGTAGTGGAGCACTGGCCCATAGCCAGG
H23A Upper
GGCTATGGGCCAGTTCTCCACTAGCTAGAAACTGGCCAGTATC
H23A Lower
GATACTGGCCAGTTTCTAGCTAGTGGAGAACTGGCCCATAGCC
GGCTATGGGCCAGTTCTCCACTATGTAGAAACTGGCCAGTATC
H23C Upper
H23C Lower
GATACTGGCCAGTTTCTACATAGTGGAGAACTGGCCCATAGCC
GGCTATGGGCCAGTTCTCCACTATCTAGAAACTGGCCAGTATC
H23S Upper
H23S Lower
GATACTGGCCAGTTTCTAGATAGTGGAGAACTGGCCCATAGCC
R24A Upper
GGGCCAGTTCTCCACTACACGCTAACTGGCCAGTATCTTTG
CAAAGATACTGGCCAGTTAGCGTGTAGTGGAGAACTGGCCC
R24A Lower
GATTACCCTGTCGCGTATGCTAGTTGGGCTAATTTAAGTTTAG
C57A Upper
C57A Lower
CTAAACTTAAATTAGCCCAACTAGCATACGCGACAGGGTAATC
S38A Upper
GATTACCCTGTCGCGTATTGTGCTTGGGCTAATTTAAGTTTAG
S38A Lower
CTAAACTTAAATTAGCCCAAGCACAATACGCGACAGGGTAATC
GGGCTAATTTAAGTTTAGAAAATGCTATTAAATATCTTAATGATG
E67A Upper
CATCATTAAGATATTTAATAGCATTTTCTAAACTTAAATTAGCCC
E67A Lower
GTTTAGAAAATGAAATTAAAGGTCTTAATGATGTTACCTCATTAG
Y70G Upper
CTAATGAGGTAACATCATTAAGACCTTTAATTTCATTTTCTAAAC
Y70G Lower
Y70F Upper
GTTTAGAAAATGAAATTAAATTCCTTAATGATGTTACCTCATTAG
CTAATGAGGTAACATCATTAAGGAATTTAATTTCATTTTCTAAAC
Y70F Lower
CTTAATGATGTTACCGCTTTAGTTGCAGAAGACTGGACTTCAGG
S76A Upper
CCTGAAGTCC
AGTCTTCTGCAACTAAAGCGGTAACATCATTAAG
S76A Lower
GCAGAAGACTGGACTTCAGCTGATCGTAAATGGTTCATTGAC
G83A Upper
G83A Lower
GTCAATGAACCATTTACGATCAGCTGAAGTCCAGTCTTCTGC
CAGAAGACTGGACTTCAGGTGCTCGTAAATGGTTCATTGACTGG
D8 6 A Upper
CCAGTCAATGAACCATTTACGAGCACCTGAAGTCCAGTCTTCTG
D8 6 A Lower
CAGAAGACTGGACTTCAGGTGATGCTAAATGGTTCATTGACTGG
R87A Upper
CCAGTCAATGAACCATTTAGCATCACCTGAAGTCCAGTCTTCTG
R87A Lower
GCGAATAAAATTTTTAAACAAGGTCACCACGAGTTAATAACTG
Y150G Upper
CAGTTATTAACTCGTGGTGACCTTGTTTAAAAATTTTATTCGC
Y150G Lower
Y150F Upper GCGAATAAAATTTTTAAACAATTCCACCACGAGTTAATAACTGAAG
Y150F Lower CTTCAGTTATTAACTCGTGGTGGAATTGTTTAAAAATTTTATTCGC
‘Letters refer to one amino acid code. Codons shown in bold encode amino acid changes.
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DNA encoding for hlyC was prepared by PCR reactions (100 pL) containing 50 ng of
pEK50 plasmid DNA as template, 10 pL of 10X Deep Vent Polymerase buffer, 4 mM
Mg*2, 300 pM deoxynucleotides, 0.5 pM of phosphorylated HlyC upper and HlyC lower
primers, and 2 U o f Deep Vent Polymerase. The following PCR program was used: (i)

1

cycle with 2 min at 95 °C, 58 °C for 45 sec, and 30 sec at 72 °C; (ii) 30 cycles with 45 sec
at 95 °C, 45 sec at 58 °C, and 30 sec at 72 °C; and (iii) 1 cycle with 45 sec at 95 °C, 58 °C
for 45 sec, and 5 min at 72 °C. PCR was performed using a GTC-2 GeneticThermal
Cycler. Following amplification, the homogenous 513 bp product was processed through
a Promega DNA Clean-Up Kit to remove unwanted polymerase and buffer contents.
The hlyC PCR product and vector were combined at a 1:3 ratio (vector:PCR
product) and ligated using 2,000,000 units ligase per 20 pL reaction at 16 °C for 16 h.
The ligation reaction was transformed into NovaBlue cells and cells were screened for the
presence and proper orientation of the hlyC gene using colony PCR (55). Colony PCR
reactions (20 pL) contained colony lysate as template, 2 pL of 10X Deep Vent
Polymerase buffer, 4 mM Mg*2, 300 pM deoxynucleotides, 0.5 pM of HlyC Lower and
T7 promoter primer, and 0.4 U of Deep Vent Polymerase. The following PCR program
was used: (i) 1 cycle with 2 min at 95 °C, 58 °C for 45 sec, and 43 sec at 72 °C; (ii) 30
cycles with 45 sec at 95 °C, 45 sec at 58 °C, and 43 sec at 72 °C; and (iii)

1

cycle with 45

sec at 95 °C, 58 °C for 45 sec, and 5 min at 72 °C. Positive screens gave a 700 bp PCR
product. Plasmid DNA from positive colonies was transformed into BL2 l(DE3)pLysS
cells for protein expression. The plasmid encoding for His6-S-tag-HlyC fusion protein was
designated pTXC2.
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Construction of Mutant HlvCs
Site-directed mutations in hlyC were generated by a round circle PCR-based
mutagenesis procedure (60) using the plasmid pTXC2 as the reaction template. Using one
upper and lower primer for each mutation described in Table 2 led to the replication o f
both plasmid strands with the desired mutation. For example, upper and lower H23 A
primers were used to change His 23 to an alanine. The PCR reactions (SO pL) contained
SO ng of pTXC2 plasmid DNA, S pL o f 10X Pfu Turbo polymerase buffer, 200 pM
deoxynucleotides, 2.S U o f Pfu Turbo DNA polymerase, and 0.2 pM of one upper and
lower primer for the desired mutation listed in Table 2. The following PCR program was
used: (i)

1

cycle with 2 min at 9S °C, 55 °C for

with 45 sec at 95 °C, 55 °C for

1

1

min, and 12 min at 72 °C; (ii) 15 cycles

min, and 12 min at 72 °C; and (iii)

1

cycle with 45 sec at

95 °C, 55 °C for 1 min and 15 min at 72 °C. Following amplification of the mutated
pTXC2 plasmid, 20 U o f the dam methylation specific restriction enzyme, Dpn I, was
added to each amplification reaction and incubated at 37 °C for 1.5 hrs to digest the
parental, methylated (nonmutated template), supercoiled DNA. PCR reactions were
applied to a 1% agarose gel, and the presence o f a PCR product of ~ 6 kb was confirmed.
To ensure complete digestion o f the parental plasmid, a negative control PCR reaction
containing everything but the mutagenic primers was also subjected to Dpn I digestion.
PCR reactions and negative controls were transformed into XL-2 Blue Ultracompetent
cells from Stratagene. Individual colonies were screened, and plasmid DNAs from
positive colonies transformed into BL21(DE3) pLysS cells. Recombinant DNA plasmids
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were designated pTXC2 with the mutation described afterward. For example, pTXC2
H23A encodes for a His6-S-tag-HlyC with His 23 changed to alanine.

DNA Sequencing
Samples were sequenced using the T7 promoter primer except for the Y1SOF and
Y150G mutants. For these constructs the HlyC upper primer was used in the sequencing
reactions. Sequencing was done at the Molecular Genetics Facility at the University of
Georgia on an A B I373 Stretch DNA Sequencer using the TAQ Dye terminator chemistry
method (61, 62).

Protein Expression and Purifications

Expression and Purification of ProHlvA
ProHlyA was isolated from inclusion bodies in BLR(DE3)pLysS or BL21(DE3)
pLysS cells containing p T X A l. Cells (200 mL culture) were grown in LB at 37 °C,
induced with

1

mM IPTG at A<soo«« 0.6, and harvested 2 h later. Subsequent steps were at

4 °C. Cells were harvested at 10,000 x g for 10 min, resuspended in 5 ml o f HED buffer
[23 mM HEPES (pH 8.0), 5 mM EDTA, 2 mM DTT] and stored at -20 °C. Upon
thawing, cells were exposed briefly to ultrasound. Inclusion bodies were collected by
centrifugation at 20,000 x g for 20 min and washed with 23 mL portions of the following
solutions: 0.3% sodium deoxycholate in HED buffer, twice with 0.1% sodium
deoxycholate in HED buffer, and finally three times with HED buffer without
deoxycholate. ProHlyA was solubilized in 0.6 mL of HED buffer containing 6 M urea for
1.3 h. Following centrifugation at 30,000 x g for 30 min, the clarified solution was

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

18

divided into aliquots and stored at -20 °C. Urea-containing buffers were always freshly
prepared.
Secreted proHlyA was obtained from the supernatant solution o f a 1.0 L
BLR(DE3 VpTXA 1 culture. Cells were removed by centrifugation. ProHlyA was
precipitated at 65% (NH^SC^ saturation and stirred for 16 h at 4 °C. After
centrifugation at 25,000 x g for 30 min, the precipitate was washed with 0.2 M citrate (pH
3.0). The precipitate was dissolved in 3.0 mL o f HED buffer containing 6 M urea and
stored in aliquots at - 2 0 °C.

Expression and Purification o f HlvCs
Cells (200 mL culture) for HlyC expression were grown in minimal media at
37 °C, induced with

1

mM IPTG at Awomn 0 .6 , harvested 4-5 h later, resuspended, and

stored in 5 mL o f HED buffer at -20 °C. HlyC was expressed as an S-tag or His6-S-tag
fusion protein using pTXCl or pTXC2 respectively. The fusion protein was isolated at 4
°C generally from inclusion bodies or occasionally from the soluble portion of cells.
Thawed cells were briefly exposed to ultrasound. Soluble fusion protein was obtained
from the cell lysate supernatant by centrifugation at

1 0 0 ,0 0 0

x g for

1

h and stored at

-20 °C. Alternatively, inclusion bodies from either pTXCl or pTXC2 cells were isolated
from the cell lysate pellet (200 mL culture) collected by centrifugation at 20,000 x g for
20 min. Inclusion bodies were washed three times with 25 mL portions of HED buffer.
The HlyC was solubilized by suspending the inclusion bodies in 15 mL o f HED 6 M urea
buffer for 1.5 h. The fusion protein solution was clarified by centrifugation at 30,000 x g
for 30 min. The solution was processed one of several ways:
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First, protein from inclusion bodies was refolded by stepwise removal o f urea by
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dialysis ( 8 Mr cutoff). The protein solution in 6 M urea was dialyzed against 1.0 L of
HED 3 M and 1 M urea buffers, each for 3 h, and finally against HED buffer for 16 h.
The solution was clarified by centrifugation at 30,000 x g for 30 min. Fusion protein was
precipitated overnight at 65% (NH«)2S0 4 saturation, collected by centrifugation at 30,000
x g for 30 min, and dissolved in HED buffer. Protein was 2 mg.
To obtain highly purified S-tag-HlyC fusion protein from BL21(DE3)pLysS/
pTXCl cells, an S-protein affinity medium was used (63, 64). Fusion protein, 2 mg, was
incubated overnight in 25 mM HEPES (pH 8.0), 0.15 M NaCl, 0.01% Triton X-100, 2 M
urea with 1 mL o f Spectra/Gel A4 which contained S-protein affinity ligand. The medium
was washed with 50 mL of the same buffer followed by 30 mL 10 mM bisTris (pH 6.2),
0.15 M NaCl, 2 M urea. Fusion protein, 0.9 mg, was released from the affinity column
with 100 mM glycine (pH 3.0), 2 M urea and dialyzed against 25 mM MES (pH 6 .1), 2 M
urea followed by HED 2 M urea buffer. Finally, it was freed of urea by dialysis against
HED buffer and clarified by centrifugation at 30,000 x g for 30 min.
To purify the His6-S-tag-HlyC, the protein was bound to an affinity His-Bind metal
chelation resin containing immobilized Ni2* ions. His6-S-tag-Hly€ was isolated from
inclusion bodies from 500 mL o f BL21(DE3)pLysS/pTXC2 cells as described above. 15
mg of protein in 7.5 mL of 20 mM Tris-HCl (pH 7.9), 0.5 M NaCl, 5 mM imidazole, 6 M
urea was applied to a 1.5 mL column o f His-Bind resin at a flow rate o f 10 column
volumes/h. The column was washed with 20 mL of 20 mM Tris-HCl (pH 7.9), 0.5 M
NaCl, 5 mM imidazole, 6 M urea followed by 20 mL o f 20 mM Tris-HCl (pH 7.9), 0.5 M
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NaCl, 20 mM imidazole, 6 M urea or until the A2S0 nmwas <0.01. His6 -S-tag-HlyC was
eluted with 20 mM Tris (pH 7.9), 0.5 M NaCl, 500 mM imidazole, 6 M urea. Urea was
removed by stepwise dialysis as described above and the solution clarified by
centrifugation at 30,000 x g for 30 min. The purified His*-S-tag-HlyC was stored in
aliquots at - 2 0 °C.

Expression and Purification o f HlvA
HlyA was obtained from the supernatant solution o f a culture o f HMS174
containing the plasmid pEK50 encoding for the complete hlyCABD operon. Cells were
grown in LB to A«ooan 10 and centrifuged 10,000 x g for

10

min at 4 °C. Subsequent

handling was at 4 °C. The solution was filtered through a 0.45 pm filter, and the filtrate
was brought to 65% saturation with ammonium sulfate. The precipitate was processed
like that described for secreted proHlyA. HlyA was freshly prepared for each group of
experiments and the preparations checked for viability at the time o f use by erythrocyte
lysis (described below).

Expression and Purification o f Acvl-ACPs
Radiolabelled acyl-ACPs were prepared using radioactive fatty acids. Acyl-ACPs
were prepared by Dr. Lesa Worsham from E. coli ACPSH and acyl-ACP synthase (65, 66,
67) as described by Trent and colleagues (58).
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Expression and Purification of f l- l4C1ACPSH
ACPSH was isotopically labeled by adding 2 pM [ l- MC]sodium pantothenate (0.6
pCi) (68, 69) to SO mL cultures o f £ coli grown and processed to purify ACPSH as
described (55). The purified ACPSH had a specific radioactivity o f 0.3 Ci/Mol and was
prepared by Dr. Lesa Worsham.

Protein Concentration
Protein concentrations were measured by the Bradford assay (70).

Protein Gel Electrophoresis. Western Blotting, and Fluorographv
SDS-PAGE followed the procedure of Laemmli (71). A Bio-Rad Semi-Dry
Electrophoretic Transfer Cell was used according to the manufacturer’s instructions for
Western Blots. Protein was transferred onto 0.4S pm nitrocellulose for 30 min at IS V.
Autofluor from Midwest Scientific was used for fluorography. Gels were dried according
to the manufacturer’s instructions using the Bio-Rad Gel Dryer and exposed to BioMax
MR film using a Kodak Biomax Transcreen-LE Intensifying Screen.

Assay of Acyltransferase Activity
The assay was done in microfuge tubes in a total volume o f 100 pL in 100 mM
HEPES (pH 8.0), 2 pM [ l4C]acyl-ACP, 22 pg proHlyA (~2 pM ), and HlyC (55 pg of
soluble cell lysate, ~0.025 pM or 10 pg of protein extracted from inclusion bodies, ~2
pM). The urea concentration did not exceed 0.4 M. Reaction was started by the addition
of [uC]acyl-ACP. Following a 5 min incubation at 4 °C, reaction was stopped by placing
the tubes in an 80 °C bath for twenty min. Enzyme was inactivated immediately; however,
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longer incubation at 80 °C was shown to enhance the precipitation of the [l4C]acylHlyA. 233 pL of saturated (NH 4>2S0 4 in 500 mM Tris (pH 7.0) was added to achieve
70% saturation. After 30 min at 4 °C, precipitated protein was collected by centrifugation
at 13,600 x g for 5 min. Acyl-ACP does not precipitate under these conditions. The
pellet was washed and vortexed with 500 pL 50% isopropanol, and the precipitate was
collected and dissolved in 1 mL o f 0.2 M NaOH. The radioactivity of a 0.9 mL aliquot
was measured in 5 mL of Ultima Gold Scintillation fluid.
In some cases, -2 pM native and mutant HlyCs were assayed by a quick dilution
method. For these reactions, enzyme isolated from inclusion bodies was immediately
diluted in 25 mM Hepes (pH 8.0) until the urea concentration was 0.4 M. The protein
was incubated on ice for 25 min, followed by the addition of the substrates, proHlyA and
[uC]acyl-ACP, and assayed as described above.

Kinetic Mechanism o f HlvC

Determination of Kinetic Parameters
Reaction velocities were measured using the assay described above under
conditions where rates were linear with time. Kinetic data were analyzed using a
computer program previously described (72) which calculated kinetic parameters by
several different methods and by the nonlinear regression analysis o f Wilkinson (73); the
different methods o f computing kinetic constants agreed with R values greater than 0.96.
or else the data were rejected. Reported kinetic constants for the different acyl-ACP
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substrates were those computed from the Direct Linear analyses (74) using the
nonlinear regression analysis o f Wilkinson (73).

Steady State Kinetics and Product Inhibition Studies
Reaction velocities and kinetic data were determined as described above. The
different methods o f computing kinetic constants agreed giving R values greater than 0.97
except for product inhibition experiments that contained both proHlyA and HlyA. At
higher concentrations proHlyA and HlyA have a tendency to aggregate (75, 76), and R
values in these circumstances ranged from 0 .91 to 1. Description o f kinetic data plots are
given in the individual figure legends.
Product inhibition studies were performed as described above except for those
containing HlyA. Assays in which HlyA product inhibition was measured contained 1.5 M
urea, in order to discourage aggregation of HlyA; this concentration of urea had no
detectable effect on the other proteins in the assay.

Chemical Cross-Linking of Proteins Involved in ProHlvA Acvlation and Acyl-Enzvme
Intermediate Formation
The reaction was set up as described above for assay o f acyltransferase activity
with the cross linking reagent, dimethyl suberimidate (DM S), added last. Any variations
in substrates are given in Figure legends 2, 32, and 33. The reaction mixes were exposed
to 10 mM DMS for 10 min at 2S °C. Chemical cross-linking was halted by the addition of
1 M ammonium acetate to a final concentration o f 100 mM, and proteins were
precipitated at 4 °C with 10% trichloroacetic acid. After I h, precipitated protein was
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collected by centrifugation at 13,600 x g for 5 min, washed with 500 pL acetone, and
the pellet collected by centrifugation. Protein was dissolved in 20 pL

8

M urea + 20 pL 2

% SDS sample buffer and subjected to SDS-PAGE followed by fluorography. For acylenzyme intermediate formation for both native and mutant HlyCs, protein mixes were
incubated for 10 min at 4 °C without DMS. Protein was precipitated with trichloroacetic
acid and processed as described above.

Assay for the Formation of Acvl-f UC]ACPSH from Acvl-HlvC and [l4ClACPSH
acyl-ACP + HlyC <-> [HlyC • acyl-ACP] <-> acyl-HlyC + ACPSH
The assay for the transfer of a long chain fatty acyl group from the enzyme
intermediate, acyl-HlyC, to radiolabeled ACPSH as described by the equation above was
as follows: Using the HlyC assay conditions described above, unlabeled myristoyl-ACP,
25 p M , was incubated with either 25 or 50 pM HlyC for 10 min at 4 °C in order to form
the putative reaction intermediate, unlabeled acyl-HlyC. The reverse reaction was begun
by the addition o f 25 pM [,4C]ACPSH followed by a 10 min incubation at 4 °C.
Following reaction, samples were made 10% in trichloroacetic acid and kept on ice for 45
min then centrifuged at 13,600 x g for 5 min. The protein pellet was washed with 500 pL
o f cold acetone, dissolved in 25 pL 8 M urea + 20 pL 2% SDS sample buffer, and
subjected to 15% SDS-PAGE followed by fluorography. Control reactions, which were
processed identically, included the following combinations: 25 pM myristoyl-ACP + 25
pM [UC] labeled ACPSH; 50 pM HlyC + 25 pM [WC] labeled ACPSH; and 25 pM [UC]
labeled ACPSH.
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pH Activity Studies
Acyltransferase acitvity was assayed at a variety o f pHs as described above using a
Mes, Hepes, Tris, Glycine buffer system. Buffers were mixed together and used as a
single buffer system titrated to the desired pH. All buffers in the assay were at a final
concentration o f 100 mM and NaCl was added to maintain an ionic strength of 0.52 M.

Chemical Modification o f HlvC
Chemical modifications of HlyC with a variety o f group specific reagents were
carried out primarily according to published procedures (77). The modification reactions
were imitated by the addition of freshly prepared chemical reagents in a particular solvent
to S-tag-HlyC isolated from inclusion bodies as described above. For each modification
reaction, a control reaction was subjected to the same treatment with solvent only. All
results were expressed as the percentage of the control activity. For each chemical
modification reaction, the reagent was either removed by physical means or the reaction
quenched as described below. Controls were done to ensure that the chemical modifier
was completely removed before assay.

Modification bv N-ethvlmaleimide (NEM1 p-Chloromercuribenzoate (PCMB’l
A 260 mM solution o f NEM was prepared in water and the concentration
determined by measuring the Ajo2 « using an extinction coefficient o f620 M 'lcm' 1 (78). A
1 mL protein solution (2.5 mg) in 0.1 M KPO4 (pH 7.0) buffer containing S-tag-HlyC was
treated with 1.0 mM NEM at 25 °C for 15 min. Excess reagent was removed by
application of the reaction to a 10 mL Sephadex G-25 fine column equilibrated in 25 mM
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Hepes (pH 8.0) buffer. Protein was eluted with 25 mM Hepes (pH 8.0) buffer
containing 0.1 M NaCl. Fractions were measured for A210» and a portion o f the peak
fraction (-1 0 fig protein) assayed for acyltransferase activity.
A stock solution o f PCMB was prepared by dissolving the solid in 0.1 M Tris (pH
11.0) buffer, followed by centrifugation at 30,000 x g for 30 min to remove insoluble
material. A 10 mM PCMB working solution was prepared by diluting a portion of the
stock solution in 0.01 M KPO4 (pH 7.0) buffer. The concentration of the PCMB solution
was determined by measuring the A233 •»>using an extinction coefficient of 1.69 x 104
M ’lcm'1(78). 100 pL o f a 2.1 pg/pL HlyC solution in 20 mM Mes (pH 6.0) buffer was
exposed to 1.0 mM PCMB by addition o f a portion of a 10 mM PCMB solution.
Reaction proceeded for 10 min at 25 °C, and the excess reagent was removed using a
centricon with a 5,000 MW cut-off. Following washing with 300 pi o f HED buffer, 10 pg
of modified protein was assayed for acyltransferase activity.

Modification bv Phenvlmethvlsulfonvl Fluroide (PMSF1 and 4-(2-Aminoethvnbenzencsulfonvl Fluoride (AEBSF1
Ten mM solutions of PMSF and AEBSF were prepared by dissolving the solids in
dry isopropanol and dimethyl sulfoxide respectively. For both inhibitors, a 1.37 pg/pL
HlyC solution in 100 pL o f 25 mM Hepes (pH 8.0) was modified by 1.0 mM o f the
reagent for 10 min at 25 °C. Following reaction, the reagents were removed using a
centricon with a 5,000 MW cut-off and the sample washed with 300 pi o f HED buffer.
Ten pg o f protein was assayed for acyltransferase activity.
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Modification bv Diethvlpvrocarbonate (DEPO
A 65 mM DEPC stock solution was prepared in acetonitrile. The concentration of
the reagent was determined by reaction with 10 mM imidazole in 0.1 M K P04 (pH 6.0)
buffer and measuring the increase in A24o«i using an extinction coefficient o f 3200 M '1cm'1
for the modified imidazole derivative (79). A 22 pL 2.0 pg/pL HlyC solution in 0 .1 M
KPO4 (pH 6.0 or pH 8.0) buffer was exposed to various amounts of DEPC at 25 °C for
10 min and the reaction quenched by the addition of a 20-fold molar excess o f imidazole in
0.1 M KPO4 (pH 6.0 or pH 8.0) buffer. To measure the modification reaction over time,
a larger reaction was prepared, and at timed intervals, 10 pg aliquots containing enzyme
were removed, quenched, and assayed. The presence o f imidazole had no effect of
acyltransferase activity.

Hvdroxvlamine (NH>OH 1 Treatment of Modified HlvC
Following treatment with 2 mM DEPC and quenching as described above, 2 M
NH 2OH (pH 7.0) was added to a final concentration of 100 mM. At various time
intervals, 10 pg aliquots o f enzyme were removed and assayed as described above.
Activity was expressed as the percentage o f a control HlyC sample (10 pg) treated with
acetonitrile and 100 mM NH2OH for 240 min.

Modification bv Tetranitromethane (TNM )
Modification o f HlyC by TNM was carried out by the addition o f various amounts
o f an ethanol solution o f the reagent (10 mM) to a 100 pL solution o f enzyme at 0.95
pg/pL in 0.05 M Tris (pH 8.0) or 0.1 M KPO4 (pH 6.0) buffers at 25 °C. Reactions were
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quenched by the addition of a 20-fold molar excess o f L-tyrosine in 0.05 M Tris (pH
8.0) buffer and 10 pg of modified enzyme assayed as described above. To measure the
modification reaction over time, a larger reaction was prepared, and at timed intervals, 10
pg aliquots of enzyme were removed, quenched, and assayed. The presence of excess
tyrosine had no effect on acyltransferase activity.

Modification with N-acetvlimidazole (NAD
N A I was prepared from acetic anhydride (100 mmol) and imdiazole (87 mmol) as
described by Staab and Rohr (80). The product was dissolved in warm acetone and
precipitated with the addition of petroleum ether and the crystals dried and stored
dessicated at -20 °C. Concentration of the reagent in acetonitrile was determined
spectrophotometrically at 240 nm using an extinction coefficient o f 3200 M*1cm*1.
Chemical modification of HlyC by N A I was carried out by the addition of a freshly
prepared acetonitrile solution o f the reagent (100 mM) to a 50 pL 0.2 pg/pL enzyme
solution in 50 mM Hepes (pH 7.5). The reaction was performed for 30 min at 25 °C.
Following modification, the reagent was removed by 70% (NH^SC^ precipitation and the
enzyme dissolved in 25mM Hepes (pH 7.0) buffer. 10.0 pg of modified HlyC was
measured for acyltransferase activity at a pH of 7.0.

Modification with Phenvlglvoxal (PG)
A 200 mM solution o f PG was prepared in 25 mM Hepes (pH 8.0) containing 50%
ethanol. The reagent was added to a 50 pL, 0.2 pg/pL, HlyC solution in 25 mM Hepes
(pH 8.0) buffer at 25 °C for one hour. Reactions were quenched by the addition o f 20-
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fold molar excess of L-arginine in 25 mM Hepes (pH 8.0) and 10 pg o f modified
protein assayed for acyltransferase activity. Excess arginine had no effect HlyC activity.

Substrate/Product Protection Studies
Chemical modification protection experiments were performed by incubating 10
pg of enzyme solution in 100 pi o f HED buffer for 5 min with either 2 pM unlabeled
myristoyl-ACP or ACPSH followed by chemical modification by one of the reagents
described above. Enzyme was treated with either 2 mM DEPC, 5 mM PG, or 50 fold
molar excess o f TN M (0.22 mM). Prior to assay, samples were precipitated at 70%
(NH^SC^ saturation at pH 7.0 at 4 °C and the enzyme was collected by centrifugation.
Neither acyl-ACP nor ACPSH precipitates under these conditions, therefore any species
o f ACP were removed. The enzyme was then assayed using [ l- wC]myristoyl-ACP as
described above.

Spectral Studies
Modification o f HlyC by DEPC or TNM was monitored spectrally using a HP
8452A Diode-Array Spectrophotometer at wavelengths ranging from 200-500 nm at 2 nm
increments. For both reactions, a double sectored cuvette was used with the enzyme
solution placed in the first sector and the modifying reagent placed in the second. For
DEPC modification, a 1.0 mg/mL HlyC solution in 0.1 M KP04 (pH 6.0) was modified
with 1.0 mM DEPC at 25 °C. A spectrum was taken before mixing o f the two solutions
that served as the blank. Reactions were initiated by mixing the contents o f the two
sectors by inversion o f the cuvette and spectra taken at various time intervals. For study
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of spectral changes attributed to TNM modification, a 2.72 mg/mL HlyC solution in
0.05 M Tris (pH 8.0) was modified with a 50-fold molar excess o f TN M (6.0 mM) at 25
°C. A spectrum was taken before mixing and one 30 min after initiation of reaction. For
both spectra, 0.05 M Tris (pH 8.0) buffer served as the blank.

Characterization o f HlvC Mutants
Mutant HlyCs were purified from inclusion bodies as described above. Mutants
were characterized like the native HlyC by performing chemical cross-linking reactions,
detection of acyl-enzyme intermediate, and determination of Km and V™ for both
proHlyA and myristoyl-ACP substrates as described above.

Assessment o f HlvA Lvtic Capability
HlyA as an agent of erythrocyte lysis was measured in 0.05% suspensions of
erythrocytes as described (81). Assays o f proHlyA activation were done as described
above except the reaction was stopped with 300 mM DTT which destroyed the thioester
acyl donors. A dose-response curve was obtained for each separate acyl-HlyA formed
from the corresponding acyl-ACP. In order to compare lytic capabilities of the separate
acyl-HlyA’s, 20 pL aliquots of enzyme assay reaction mixtures immediately after
completion and cessation o f reaction, each containing a different acyl-ACP, were assayed
for erythrocyte lysis.
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CHAPTER 3
RESULTS

Expression and Purification of Proteins
ProHlyA was expressed using recombinant DNA (p T X A l) containing the
HlyABD genes. Expression o f proHly A was independent o f different growth conditions.
Figure 2 lane 2 shows proHlyA, Mr 107,000, present in the lysate o f cells which
contained pTXAl while it was absent in cells which contained the vector, lane 3. As
anticipated, since pTXA l encodes for HlyB and HlyD, proHlyA was also isolated from
the culture medium (lane 1). Intracellular proHlyA was in inclusion bodies. Urea
extraction of the isolated and washed inclusion bodies resulted in a preparation estimated
by densitometry to contain >90% proHlyA (lane 4). The protein was stored in 6 M urea
and was stable at -20 °C for greater than 6 months. Each liter o f culture yielded -10-12
mg of proHlyA from inclusion bodies and 1.5 mg of proHlyA from the cell culture
media.
HlyC was either expressed as an S-tag or His6-S-tag fusion protein using pTXC 1
or pTXC2 respectively. The highest yields of HlyC were obtained from cultures grown
in minimal media at 37 °C harvested five hours after induction with 1 mM IPTG.
Approximately, 60 mg o f HlyC was expressed per liter of cell culture. The S-tag-HlyC
fusion protein was seen in SDS-PAGE of the total cell lysate as an intensely staining
band at Mr 22,500 (Figure 3A lane 3) localized mainly in the insoluble portion of the cell
lysate (lane 1) while a small amount was present in the soluble portion (lane 2). A lysate
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Figure 2: ProHlyA expression and purification. An SDS-10% PAGE showing
distribution and purification of proHlyA. The arrow marks the position o f the 107 kDa
proHlyA. The gel was loaded as follows: lane 1, 10 pg o f protein from the
BLR(DE3)pTXAl cell growth supernatant solution; lane 2, 10 pg o f the
BLR(DE3)pLysS/pTXAl cell lysate; lane 3, lOpg o f lysate from cells that did not
contain pTXAl; and lane 4 ,2 pg of proHlyA purified from inclusion bodies. The
migration o f mass markers is indicated on the left in kDa.
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Figure 3: Expression o f S-tag-HlyC. An SDS-15% PAGE (A) and its western blot
probed with S-protein alkaline phosphatase conjugate (B) showing the cellular
distribution of S-tag-HlyC fusion protein. Lanes in A contained 10 pg of protein from
the following sources: lane 1, insoluble fraction o f cell lysate; lane 2, soluble fraction of
the cell lysate; lane 3, cell lysate; lane 4, lysate o f cells without pTXCl. The gel in B was
loaded with the following proteins: lane 1, 3 pg o f lysate o f cells lacking pTXCl; lane 2,
1 pg of insoluble fraction of cell lysate; lane 3, 3 pg of the soluble fraction of the cell
lysate; lane 4, 1 pg o f the cell lysate. More protein was loaded into lanes 1 and 3 in order
to visualize the fusion protein, if it were present. The migration of molecular mass
markers is indicated on the left in kDa. The arrow shows the position of the fusion
protein at 22.5 kDa for both the stained gel and western blot.
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of cells lacking the recombinant DNA (lane 4) contained none. A Western blot o f the
separated proteins (Figure 3B) confirmed the presence of a small amount o f the fusion
protein in the soluble fraction which reacted with the S-peptide-conjugate probe (lane 3).
No fusion protein appeared in lysates o f cells which did not contain pTXCl (lane 1) or
which were not induced (not shown). The two dark bands (lanes 2 and 4) o f the western
blot (Figure 3B) confirmed the identity of the intensely stained Coomassie Blue bands
(Figure 3A, lanes 1 and 3) as S-tag-HlyC fusion protein. Densitometric analysis
indicated that >50% o f the insoluble protein was the fusion protein. Cellular location and
expression of the His6-S-tag-HlyC from pTXC2 was identical to that of S-tag-HlyC from
pTXC l. HlyC activity was assayed as described subsequently; sources of active enzyme
included cell lysates, the 100,000 x g solution o f the cell lysate, and urea extracts of
washed inclusion bodies.

Characterization o f HlvC-Dependent ProHlvA Activation
ProHlyA acylation was measured using defined quantities of purified substrates
(proHlyA and [uC]palmitoyl-ACP) and isolated enzyme (HlyC) under reproducible
reaction conditions. Radioactivity was transferred from acyl-ACP to proHlyA to form
HlyA in the presence o f HlyC. With proHlyA, and palmitoyl-ACP concentrations each at
2 pM and HlyC about 25 nM in the assay, about 1,500-3,000 dpm were obtained
routinely. Assay blanks which contained heat-denatured HlyC measured about 50
counts/min. HlyC source was 50 pg soluble protein o f the cell lysate, and its
concentration was estimated from western blot analyses and Novagen S-tag rapid assay
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kit. The specific activity o f the cell extract soluble HlyC was -200 nanomoles fatty acyl

group transferred/min/mg protein where HlyC was -0.1% o f the protein. In the absence
of the recombinant hlyC or its expression, there was no proHlyA-acyl-ACP
acyltransferase activity.
Fluorography of SDS-PAGE of the assay precipitates (Figure 4) showed the
transfer o f the radioactive fatty acyl group from palmitoyl-ACP (lanel) to a 107 kDa
protein, HlyA (lane 5). There was no residual radioactivdy labeled palmitoyl-ACP
following reaction termination and washing (lane 5). HlyA was labeled only when cell
lysate containing HlyC was present; cell lysate without HlyC did not cause any transfer
of radioactivity from acyl-ACP to proHlyA (lane 2). Reactions containing only HlyC and
acyl-ACP or proHlyA and acyl-ACP (lanes 3 and 4 respectively) formed no HlyA.
Densitometric analyses o f fluorographs of HlyA formed in assays paralleled the assay of
radioactivity incorporated into HlyA.
To verify that HlyC was responsible for the acyltransferase activity, both the Stag-HlyC and the HiS6-S-tag-HlyC fusion protein were solublized from washed inclusion
bodies (Figure 5A lane 3 and Figure 5B lane 2) in buffered 6 M urea and affinity purified.
S-tag-HlyC was applied to S-peptiae-iiganded Sepharose 4A. Following washing,
elution at pH 3.0, and renaturation by dialysis to HED buffer the fusion protein was seen
as a single band at M r 22,500 in Figure 5A, lane 4. -0 .4 mg/L of culture o f pure S-tagHlyC was obtained by this method. His6-S-tag-HlyC from inclusion bodies (Figure 5B
lane 2) was applied to an affinity His-Bind metal chelation resin containing immobilized
N i2+ ions. Following washing and elution with 500 mM imidazole, the His6-S-tag-HlyC
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Figure 4: Dependence o f acyl-ACP-proHlyA acyl transfer on HlyC. Fluorography of an
SDS-12% PAGE of redissolved assay precipitates showing the transfer of radiolabeled
fatty acid from acyl-ACP (Mr -9,000) to proHlyA forming radiolabeled HlyA (Mr
107,000). The method was that of Worsham and colleagues (82), and Kodak X-OMAT
LS film was used. Although acyl-ACP does not precipitate under the conditions used to
separate the reaction product HlyA, any entrapped thiol esters were removed by
dissolving the assay precipitates in 100 pi 25 mM HEPES (pH 8.0), 1 mM DTT, 5 mM
EDTA, 5 M urea and treated with 100 pi 2 M NH 2OH (pH 10.0) for 30 min at 37 °C.
Following precipitation with cold trichloroacetic acid, samples were dissolved in SDSPAGE sample buffer. [ l- u C]palmitoyl-ACP, 0.4 pg, was applied to lane I; other lanes
contained material from assays. Lane 2 assay contained proHlyA, acyl-ACP, and lysate
from cells which did not contain pTXCl. Lane 3 assay contained acyl-ACP and
BLR(DE3)pLysS/pTXCl cell lysate. Lane 4 assay contained proHlyA and acyl-ACP.
Lane 5 assay contained acyl-ACP, proHlyA and BLR(DE3)pLysS/pTXCl cell lysate.
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Figure 5: Purification o f S-tag- (A) and (B) His6-S-tag-HlyC. (A) SDS-15% PAGE
illustrating the S-tag-HlyC purification as described in the text. Proteins from the
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Figure S (continued): following sources were loaded in S pg aliquots: lane 1, mass
standards in kDa; lane 2, unwashed inclusion bodies; lane 3, washed inclusion bodies;
lane 4, pH 3.0 eluate from S-protein affinity chromatography; lane S, TSK-250 HPLC
(Figure 7) peak fraction of acyl-ACP-proHlyA acyltransferase activity. (B ) SDS-15%
PAGE illustrating the His6-S-tag-HlyC purification as described in the text. Proteins
from the following sources were loaded in 10 pg aliquots: lane 1, mass standards in kDa;
lane 2, washed inclusion bodies; lane 3, flow through; lane 4, 20 mM imidazole wash;
lane S, 500 mM imidazole eluate from the His-Bind metal chelation resin.
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fusion protein electrophoresed at a M r o f23,000 as shown Figure SB lane S. The yield of

pure HlyC by this method was ~8 mg/L o f culture. The purified HlyC from the
imidazole elution was renatured by dialysis against HED buffer. The pure His6-S-tagand S-tag-HlyCs both possessed acyl-ACP-proHlyA acyltransferase activity. The
activities and stabilities of these preparations is discussed below.
The fused tags attached to the N-terminus of HlyC did not influence
acyltransferase activity. The acyl-ACP-proHlyA acyltransferase activities o f two aliquots
of soluble S-tag-HlyC from cell lysate were measured. One aliquot contained fusion
protein while the other had been treated with thrombin to cleave the fusion protein to
HlyC and S-tag. Fusion protein cleavage was monitored by S-peptide-conjugate probes
of Western blots of SDS-PAGE. Exposure to thrombin overnight at 4 °C or for 2 h at
25 °C resulted in disappearance o f S-peptide-probe reactivity upon SDS-PAGE Western
blots (data not shown). S-tag or His6-S-tag-HlyC fusion proteins and HlyC resulting
from thrombin cleavage showed the same amount of acyltransferase activity.
A demonstration o f the thrombin cleavage is shown in Figure 6. An S-peptide
probe o f an SDS-PAGE western blot shows the purified S-tag-HlyC (Figure 6B, lane 5);
following exposure to thrombin, the S-tag was removed by proteolytic cleavage (lane 4).
A Coomassie stained gel o f the same material is shown in lanes 2 (after thrombin
treatment) and 3 (before thrombin treatment). A barely visible band near the 32.5 kD
molecular weight marker is thrombin. The removal of the S-tag and its thrombin
cleavage site changed the Mr o f the protein band from 22,500 to -19,000, the size of
HlyC monomer deduced from its DNA sequence (18,458).
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Figure 6: Thrombin Cleavage of S-tag-HlyC. SDS-15% PAGE and Western blot
showing thrombin cleavage o f S-tag-HlyC fusion protein. Proteins in lanes 1-3 were
stained with Coomassie Blue, and proteins in lanes 4 and 5 were Westem-blotted and
probed with S-peptide-alkaline phosphatase conjugate. Lane 1, mass standards in kDa;
lanes 2 and 3 each contained 5 pg of fusion protein, lane 2 after treatment with thrombin
and lane 3 before treatment. Lanes 4 and 5 were each loaded with 1 pg of fusion protein
after and before exposure to thrombin, respectively.
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Table 3. COMPARISON OF HLYC ACYLTRANSFERASE ACTIVITIES
Source of HlyC

Specific Activity*

100,000 x g supernatant of cell lysate

200,000

Urea Extracts o f Washed Inclusion Bodies

502

Eluate from S-Protein affinity resin (Pure S-tag-HlyC)

278

Eluate from His-bind resin (Pure HiS6-S-tag-HlyC)

1100

*units are pmol o f fatty acyl group transferred/min/mg protein

Although the eluate from the S-protein affinity resin resulted in a highly purified
and active fusion protein, the relatively harsh conditions o f purification and renaturation
lowered the specific activity compared to that of soluble HlyC which had never been in
inclusion bodies nor exposed to urea. A more active preparation o f HlyC from 6 M urea
was obtained by step wise removal of the denaturant by dialysis. The specific activity o f
the resulting enzyme solution was S02 pmol o f acyl group transferred/min/mg of protein
where HlyC was estimated as >50% o f the total protein. This preparation was used
routinely for studies o f the enzyme. Purified His6-S-tag-HlyC resulted in a preparation of
similar activity (Table 3).
The size o f the active form of HlyC was shown by size exclusion HPLC to be
-22,500 Mr where fraction 29 showed the highest activty (Figure 7). Thus HlyC was
enzymatically active as a monomer. The largest Ajgonm peak in Figure 7, fraction 38,
was DTT in the sample applied.

SDS-PAGE of the protein from the fraction which
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Figure 7: Size exclusion HPLC showing Mr of acyl-ACP-proHlyA acyltransferase
activity. 0.3 mg of S-tag-HlyC in 25 mM HEPES (pH 8.0), 5 mM EGTA, 1 mM DTT,
0.3 M urea, extracted from inclusion bodies was applied to a TSK-250 column (Bio-Rad)
on a Waters model 510 HPLC. Column and elution buffer was 25 mM HEPES (pH 7.2),
0.05 M NaCl. Fractions of 0.5 ml were collected, measured for A280 (□) and acyl-ACPproHlyA acyltransferase activity (o). Protein from the peak fraction of enzyme activity
was analyzed by SDS-PAGE, Figure 5A lane 5. Arrows denote elution peaks of
calibration proteins o f the indicated sizes in kDa.
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contained the highest acyltransferase activity (Figure 5A lane S) showed a single protein,
the size of HlyC.
The reaction rate was linear with respect to HlyC concentration (Figure 8), and
the amount of product formed was linear with time at 4 °C (Figure 9). Michaelis-Menten
kinetics were observed. With myristoyl-ACP held constant at 1 pM, proHlyA had a
Km*w of 0.94±0.1pM and V max*pp 7.5±0.2, and myristoyl-ACP had a Km*ppo f 0.48±0.1
pM, and a Vmu*ppof 6.9±0.5 with proHlyA held constant at 2 pM. Diverse acyl-ACPs
served as substrates, but when [ l- 14C]palmitoyl-CoA was substituted for radiolabeled
acyl-ACP, there was no incorporation of radioactivity into proHlyA. The presence of
urea, up to 3 M, had no effect on the assay. Storage of HlyC in > 0.5 M urea, however,
was not tolerated. A variety o f cations and anions were examined, and the assay was
insensitive to ionic strength and ions, with a notable exception. Ca2+was inhibitory.
Deleterious effects of Ca2*on proHlyA activation were seen at assay ion concentrations
above SO pM, and concentrations >200 pM practically halted toxin formation (Figure
10). The acyltransferase activity was relatively stable. It remained constant indefinitely
at 4° C or -20° C, but at 25 °C for 16 h about one half of the activity survived. Enzyme
was destroyed quickly at higher temperatures. Several freeze-thaw transitions were
tolerated with no diminution o f activity.
The pH dependency o f the enzyme catalyzed acylation o f proHlyA was measured
over a range of pH at constant ionic strength (Figure 11). Acyltransferase activity was
undetectable below pH 6.0 and increased sharply between pH 6.5 and 7.5, with maximal
activity seen at pH 9-10. Activity fell sharply at pH>!0.0. The formation o f the
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Figure 8: Dependence of acyl-ACP-proHlyA acyl transfer reaction on HlyC.
Assays were done as described in Materials and Methods in the presence of increasing
amounts of cell lysate which contained S-tag-HlyC fusion protein.
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Figure 9: HlyC acyltransferase activity as a function of time. Assays were done as
described in Materials and Methods at various time intervals.
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Figure 10: Effects of Ca2+ on HlyC acyltransferase activity. The assay was earned out as
described in Materials and Methods except that increasing amounts of Ca2* were added.
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Figure 11: Effects of pH on HlyC acyltransferase activity at constant ionic strength.
Assays were performed at different pH as described in Materials and Methods.
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radiolabelled product, HlyA, at various pHs was also examined by fluorography of
redissolved assay precipitates and showed the same trend with pH (data not shown).
Chemical cross-linking of proHlyA, [I4C]acyl-ACP, and HlyC in different
combinations followed by SDS-PAGE and fluorography resulted in visualization of
discrete protein-protein complexes (Figure 12). Dimethylsuberimidate (DMS) treatment
of solutions which contained all three proteins, the complete reaction mixture, resulted in
the detection of HlyA only, at Mr 107,000, with no evidence of heterotrimer or
heterodimers at higher molecular weights (lane 6). Exposure of a solution of [ ,4C]acylACP and proHlyA to DMS (lane S) did not result in any complexes except those
generated from [14C]acyl-ACP alone (lane 2). Similar treatment of a solution of
[l4C]acyl-ACP and HlyC resulted in a complex at Mr -34,500, a heterodimer, (lane 3).
The Mr -34,500 band was not seen when [I4C]acyl-ACP alone was subjected to chemical
cross-linking. In addition, a faint, unique band was seen at Mr-23,000 (arrow), the size
expected for an acyl-HlyC monomer. If HlyC was denatured by exposure to 5 M urea
prior to chemical cross-linking, no heterocomplex or acyl-HlyC were formed (lane 4).
When a solution of HlyC ar.d [l4C]acyl-ACP was prepared with no exposure to DMS and
subjected to SDS-PAGE and fluorography, a band at M r-23,000 was evident (lanes 8
and 9); the presence of acyl-HlyC-S-tag was confirmed by reaction of the western blotted
band with S-protein conjugated alkaline phosphatase (data not shown). Furthermore, as
seen by comparing lanes 8 and 9, the amount of acyl-enzyme increased when the
concentration o f HlyC in the solution was increased. A solution containing HlyC and
[14C]acyl-ACP was prepared and divided into two parts. Nothing was added to one
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Figure 12: Fluorographic demonstration of acyltransferase reaction proteins which crosslinked in the presence of DMS (dimethylsuberimidate) and the formation of an acylenzyme intermediate (arrow) with and without DMS treatment. Lane I contained
[14C] labeled mass standards in kDa. Lanes 2 through 6 contained combinations of
acyltransferase reaction proteins exposed to DMS, subjected to SDS 12% PAGE, and
fluorograped as described (82). Kodak BioMax MR film was used. Each assay treated
with DMS contained 2 pM [I4C]myristoyl-ACP plus the following proteins: lane 2,
none; lane 3,2.5 pM HlyC; lane 4,2.5 pM HlyC that had been exposed to 5 M urea
overnight and in the reaction; lane 5, 2.3 pM proHlyA; lane 6, 2.5 pM HlyC + 2.3 pM
proHlyA. Lanes 7 through 10 were assay mixes which were incubated for 10
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Figure 12 (continued): min at 4°C and were not exposed to DMS. Each contained 2 pM
[uC]myristoyl-ACP plus the following proteins: lane 7, none and lane 8, 10 pM HlyC.
Lanes 9 and 10 arose from a single 200 pi acyltransferase assay which contained the
indicated acyl-ACP + 20 pM HlyC; it was divided into two 100 pi aliquots after
incubation. To one aliquot was added nothing (lane 9) while 10 pM proHlyA was added
to the other (lane 10); after an additional 10 min incubation at 4 °C, both were processed
as described in Materials and Methods.
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portion while proHlyA was added to the other. Both solutions were processed like the
other protein solutions in Figure 12. The portion which had no added proHlyA contained
acyl intermediate (lane 9). The acyl intermediate disappeared from the other portion
upon addition of proHlyA and HlyA formation ensued (lane

1 0 ).

The demonstration of a reactive covalent acyl-enyzme intermediate indicated that
the acyltransferase reaction likely proceeded by two partial reactions as follows:

1) acyl-ACP + HlyC <-> [HlyC • acyl-ACP] <-►acyl-HlyC + ACPSH
2) acvl-HlvC + oroHlvA <-> foroHlvA • acvl-HlvCl <-» HlvA + HlvC
sum)

acyl-ACP + proHlyA <-> HlyA + ACPSH
Another means o f demonstrating the occurrence o f the acyl-enzyme would be to

show the reversibility o f partial reaction 1 . Radioactively labeled ACPSH was made by
purifying ACPSH from E. coli grown in the presence of [ l - l4C]pantothenate which labels
the prosthetic group covalently attached to the protein (6 8 ,6 9 ). Unlabeled myristoylACP and HlyC were mixed in an assay reaction and incubated for

10

min at 4 °C in order

to allow formation o f unlabeled acyl-HlyC, one of the two substrates in the reverse of
partial reaction 1. Then radiolabeled ACPSH, the second substrate in the reverse of
partial reaction 1, was added, and after another 10 min incubation at 4 °C, the proteins
were precipitated, redissolved, and separated by SDS-PAGE. The formation of
radiolabeled acyl-ACP from unlabeled acyl-HlyC and radiolabeled ACPSH is shown in
Figure 13 lanes 6 and 7. Twice as much HlyC was used to generate acyl-HlyC in the
reaction analyzed in lane 7 compared to that analyzed in lane 6 , and a larger amount of
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myristoyl-ACP was evident on the fluorogram. An assay that contained only acyl-ACP
and labeled ACPSH (lane 5) showed no labeled acyl-ACP so detectable amounts of
uncatalyzed acyl group exchange did not occur under the conditions employed. An assay
that contained only HlyC and labeled ACPSH showed no radioactivity at the position of
acyl-ACP (not shown). Thus HlyC in the form of acyl-HlyC catalyzed the proposed
partial reaction 1 in the reverse direction converting ACPSH to acyl-ACP.

Characterization o f Diverse Acvl-ACP Substrates Compared with Ervthrocvte Lvsis bv
the Different Acvl-Toxins
The kinetic parameters of acyl-ACP’s containing different acyl groups were
determined (Table 4). Proportionality constants, V^/K m (directly proportional to
kcai/Km), were used to compare catalytic efficiencies, and myristoyl-ACP was the most
effective substrate. Its kinetic parameters were used as a reference for comparing those
of the other substrates, shown as percentages of myristoyl-ACP values in Table 4.
Except lauroyl-ACP, the percentages of myristoyl-ACP Km fluctuated among the various
acyl-donors while there was not much variation among the Vmu percentages, except for
palmitoleoyl-ACP. Without the latter acyl-ACP, a double-reciprocal plot of the different
acyl-ACPs showed unchanging y axis intercepts and increasing slopes, as carbon chain
length increased (data not shown). This pattern describes a plot of competitive inhibition.
The two shortest chain length saturated acyl-ACPs were the most effective substrates
largely because o f their low Kmvalues, close to 0.5 pM (Table 4). Increasing chain
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Figure 13: Fluorographic demonstration of the reversibility of partial reaction 1. Protein
mixtures were prepared, treated, analyzed by 15% SDS-PAGE, and subjected to
fluorography as described in Experimental Procedures. The following proteins were
applied to lanes 1-3: lane 1, radioactive mass standards in kDA; lane 2, [I4C]myristoylACP, 20 Ci/Mol, 0.5 pg; and lane 3, [14C]myristoyI-ACP, 20 Ci/Mol, 0.25 pg . Reaction
mixtures o f 100 pL containing the indicated proteins prepared and processed as described
above were analyzed in the following lanes: lane 4, 25 pM [I4C]ACPSH; lane 5, 25 pM
[I4C]ACPSH + 25 pM myristoyl-ACP; lane 6, 25 pM myristoyl-ACP + 25 pM HlyC
followed by 25 pM [I4C]ACPSH; lane 7, 25 pM myristoyl-ACP + 50 pM HlyC followed
by 25 pM [l4C]ACPSH. The [14C]ACPSH was 0.3 Ci/Mol.
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Table 4: KINETIC PARAMETERS OF DIFFERENT ACYL-ACP’S IN THE
ACYLTRANSFERASE REACTION*

lauroyl-

12:0

0 46±0.1

96

5.7±0.2

% of
myristoylACP
83

myristoyl-

14:0

0.48±0.1

100

6.9±0.5

100

14.3

palmitoyl-

16:0

0.96±0.1

200

8.5±0.2

124

8.9

16: l*9

0.91±0.2

190

2.2±0.2

33

2.5

18:0

8.5±0.5

1771

7.0±0.1

102

0.8

18: l^9

6.4±0 6

1325

5.9±0.3

87

0.9

acyl-ACP

acyl chain

K

% of
myristoyl-

v~ mac

A C P K n * "’

palmitolcoylstearoyloleoyl-

v» rru x *w/v
r»m
'

12.3

*Km*pp is pM, and VRiaxapp is pmol acyl group incorporated/min. The assay procedure and
computation of kinetic parameters were given under Materials and Methods. Kinetic
parameters are apparent values for the particular conditions given including the
concentration of the fixed substrate, proHlyA, which was 2 pM.
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lengths o f the saturated fatty acyl-ACPs resulted in increasing Kmvalues, 0.96 jiM for
palmitoyl-ACP and 8.5 pM for stearoyl-ACP. The proportionality constants decreased
with increasing chain length. There was not much difference between oleoyl- and
stearoyl-ACP’s, but palmitoleoyl-ACP was a much less efficient substrate than
palmitoyl-ACP. The Km values, however, for each of the two unsaturated fatty acids
were lower than that of the corresponding saturated homologue, so shortening of the
carbon chain length perhaps contributed to lowering Km’ s.
The erythrocyte lytic abilities of the different HlyA’s formed by the different
acyl-ACP donors did not correspond to the amount of acyl group transferred. Thus the
extent of lysis depended upon the nature o f HlyA’s fatty acyl group rather than the
amount of toxin (Table 5). Acyltransferase assays each contained an identical amount of
a different acyl-ACP donor, and, following reaction, each had formed different amounts
of HlyA as predicted by Table 5, column 3. I f toxicity was independent of the nature of
the acyl group on the toxin, hemolysis (Table 5, column 5) should parallel toxin
formation (column 3), which it did not. Although stearoyl-ACP and oleoyl-ACP were
the least effective acyl group donors, the lesser amounts of toxins produced from them
were most lytic. The most effective acyl-ACP substrate, myristoyl-ACP, produced
product, myristoyl-HlyA, that caused half o f the lysis that stearoyl-HlyA caused, but
stearoyl-ACP-supported toxin activation produced 94% less acyl-toxin than did that
employing myristoyl-ACP. An assay which contained palmitoyl-CoA instead of acylACP did not activate toxin; nor did assays which contained only two of the three essential
components.
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Table 5: COMPARISON OF SUBSTRATE EFFICACIES OF ACYL-ACP’S W ITH
LYTIC ABILITIES OF THE CORRESPONDING ACYL-HLYA’S

12:0

amount of acyl
group transfer
(V/Km)*
12.3

amount of erythrocyte
lysis (A«3)b
0.739±0.004

lysis per unit of acyl
group transferred0
0.6

myristoyl-

14:0

14.3

0.438^0.038

0.3

palmitoyl-

16:0

8.9

0.614±0.012

0.7

16:1*

2.5

0.451*0.005

1.8

18:0

0.8

0.785*0.069

9.5

18:1*

0.9

0.813*0.112

8.7

acyl-ACP

acyl chain

lauroyl-

palmitoleoylstearoyloleoyl-

*The proportionality constant is a measure of the rate of transfer of the respective acyl
groups to proHlyA. ‘’Lysis o f 2% solutions of erythrocytes caused by the addition of
equal sized aliquots of acyltransferase assays which had been assembled with equal
concentrations of the respective acyl-ACP’s. Lysis was measured, as described in the
text, by the A543

1 :1 0

dilutions of the respective erythrocyte lysis assay supernatant

solutions. ‘The amount of lysis per unit of acyl group transferred was calculated by
dividing the A$43 (corrected for the 1:10 dilution) of the respective solutions (column 4)
by the corresponding proportionality constant for the acyltransferase activity o f that
particular acyl-ACP (column 3).
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Kinetic Mechanism o f HlvC

Steady State Kinetics of HlvC
Since myristoyl-ACP was the most effective substrate for the acyltransferase
(Table 4), it was used for determination of the steady state kinetic mechanism of HlyC.
The two-substrate reaction catalyzed by HlyC shown below,

proHlyA + acyl-ACP

HlyC

—> HlyA + ACPSH

likely proceeds by way of one of two possible reaction mechanisms which are
summarized as follows. One entails formation of a substituted enzyme intermediate
where one product is released prior to the binding of the second substrate; alternatively, a
ternary complex is formed where both substrates combine with the enzyme in either a
random or compulsory order prior to the release of any product. Steady state kinetics was
done to distinguish between the two general mechanisms. Measurements of initial
reaction velocities at varying concentrations of one substrate at several fixed
concentrations of the other substrate yielded data that in double-reciprocal and halfreciprocal plots formed patterns that distinguished between a substituted enzyme or
ternary complex mechanism. Initial reaction rates of proHlyA acylation were determined
by varying myristoyl-ACP concentrations at different fixed concentrations of proHlyA
(Figure 14) and by varying proHlyA concentrations at different fixed myristoyl-ACP
concentrations (Figure 15). In both instances, the graphs showed a series of parallel lines
on double reciprocal plots (Figures 14A and 15A) and common intersection o f all linear
plots on the [S]/v axis for half-reciprocal plots (Figures 14B and 15B). Each type of plot
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Figure 14: Myristoyl-ACP initial velocity data at different fixed non-saturating
concentrations of proHlyA shown as double reciprocal plots (A) and as half-reciprocal
plots (B).
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Figure 14 (continued): Myristoyl-ACP initial velocity data were obtained at the
following different fixed concentrations of proHlyA: V, 0.34 pM; □ 1 pM; o, 1.5 pM;
and X 2 pM. Velocitys (v) were in identical arbitrary units. The inset shows the
secondary plot graphical determination of the reaction kinetic parameters for proHlyA
from the respective half-reciprocal plot slopes (1/Vmaxapp) at different [proHlyA] (pM).
The linear correlation coefficient was 0.96.
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Figure IS: ProHlyA initial velocity data at different fixed non-saturating concentrations
of myristoyl-ACP shown as double reciprocal plots (A) and as half-reciprocal plots (B).
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Figure 1S (continued): Initial velocity data for proHlyA were obtained at the following
different fixed concentrations of myristoyl-ACP: o, 0.S pM; □, 0.7S pM; A, 1 pM; and
V, 2 pM. Velocity (v) was in arbitrary units. The inset shows the secondary plot
graphical determination of the reaction kinetic parameters for myristoyl-ACP from the
respective half-reciprocal plot slopes (1/Vmax*pp) at different [myristoyl-ACP] (pM). The
linear correlation coefficient was 0.96.
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is shown to demonstrate that data describing parallel lines on a double reciprocal plot
require convergence on the [S]/v axis o f a half reciprocal plot (S3). Throughout the
remainder of this manuscript, kinetic data are displayed as half-reciprocal (Hanes) plots
which has the best distribution of error throughout the plot (84,85). Each pattern shown
by the two plotting methods was consistent with a bi bi substituted enzyme (bi bi ping
pong) kinetic mechanism for HlyC. In contrast, a ternary complex mechanism would
show a series of plots of differing intercepts on a half reciprocal plot. The kinetic
constants of the reaction where both substrates are present in saturating amounts were
determined from secondary plots shown in the insets of Figures 14B and 1SB and also by
inserting the kinetic parameters obtained from the primary plots (Figures 14 and IS) into
rate equations (73). There was excellent agreement between the two methods. Kmmyns,oyl'
ACPwas 1.6±0.4 uM, and KmproHlyAwas 3.6±1.2 uM; V™.. was 14.0±1.8 pmoles of acyl
group transferred/min. The correlation coefficient for the determination of these three
values was 0.99 for each.

Product Inhibition Kinetics
HlyC acyltransferase activity was not effected by the addition o f unlabelled
palmitoyl-CoA or free fatty acid to the reaction. If, however, ACPSH or HlyA were
added, the reaction was inhibited. These product inhibitions allowed further
characterization of the enzyme mechanism. Initial velocity studies of a bi bi reaction can
place it into two general mechanistic groups, ping pong or sequential, while product
inhibition studies can provide a finer resolution of the kinetic mechanism. In order to
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define further the kinetic mechanism o f HlyC catalysis, the addition of different fixed
concentrations of each of the products separately to initial reaction velocity studies for
each substrate was done.
The addition of different fixed amounts of ACPSH to reactions containing
variable amounts of proHlyA resulted in a family of linear plots, which appeared parallel
on a double-reciprocal plot (not shown). The parallel lines were verified by plotting the
data on a half reciprocal plot (Figure 16) where the intercepts converged on the [S]/v axis
(83). The graphical patterns were consistent with uncompetitive inhibition where both
and Km*** decreased in response to the presence of increasing fixed amounts of
product, ACPSH. A similar pattern of inhibition was seen when different fixed amounts
of ACPSH were added to reactions where myristoyl-ACP was the varied substrate
(Figure 17). In both cases, Kmand Vm, values changed by the same factor as [I]
increased. Replots of 1/Vmax*,lp, the slopes of Figure 16 and 17, versus [I] were
hyperbolic for ACPSH product inhibition with respect to both myristoyl-ACP and
proHlyA (insets). These findings described a kind of mixed-type inhibition in which Km
and Vmax change by the same factor resulting in parallel line double-reciprocal plots (not
shown) (86). In contrast to linear uncompetitive inhibition where the curves continue to
move apart as [I] increases, the displacement between the curves in Figures 16 and 17
became limiting as [I] increased (double-reciprocal plots not shown). This was shown by
the hyperbolic replots (insets) and also by plots of initial reaction velocities against [I] at
fixed [S] which showed a leveling o f the velocities at higher [I] values rather than a
continuous decrement of initial reaction velocities as [I] increased (data not shown).
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Figure 16: ACPSH inhibition with respect to proHlyA. Evaluation of the kinetic
parameters of proHlyA at a fixed myristoyl-ACP concentration of I pM was done in the
presence of the following concentrations o f the product ACPSH: V, 10 pM; A, S pM; □,
2.5 pM; and o, 0 pM. Velocity (v) was in identical arbitrary units in all half-reciprocal
plots. The inset shows the half-reciprocal plot slopes, 1/Vmax*pp, versus the corresponding
[ACPSH] (pM).
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Figure 17: ACPSH inhibition with respect to myristoyl-ACP. Evaluation of the kinetic
parameters of myristoyl-ACP was done at a fixed proHlyA concentration of 2 pM in the
presence o f the following concentrations of the product ACPSH: V, 20 pM; A, 5 pM; □,
2.5 pM; and o, 0 pM. Velocity (v) was in identical arbitrary units in all half-reciprocal
plots. The inset shows the half-reciprocal plot slopes, 1/Vm«*pp, versus the corresponding
[ACPSH] (pM).
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Thus ACPSH inhibition with respect to both myristoyl-ACP and proHlyA at fixed,
unsaturating values of each other was mixed-type inhibition.
Prior to studying the effects o f the product, HlyA, on reaction rates, any potential
for additional acylation of HlyA was examined. Purified HlyA produced in vivo was
obtained from E. coli containing pEKSO, a plasmid encoding for the hemolysin operon.
The in vivo produced toxin was subjected to possible acylation in the assay milieu, which
contained radiolabeled myristoyl-ACP and HlyC. HlyA so treated was not acylated. It
was not visualized on fluorography after extended exposure nor was it radioactive when
isolated and measured in a liquid scintillation counter.
Upon addition o f different fixed amounts of the product HlyA to reactions
containing variable amounts of myristoyl-ACP, the resulting primary double-reciprocal
plots all intersected at the same point on the 1/v axis (not shown). In confirmation of this
pattern, the half-reciprocal primary plots (Figure 18) showed a series of parallel lines.
These findings were diagnostic of competitive inhibition. The primary plots will not
distinguish among the following types of competitive inhibition: one-site, pure
competitive inhibition; two-site, pure competitive inhibition, and partial competitive
inhibition (87). The three types of competitive inhibition can be distinguished by plotting
reaction velocity versus [I] at a fixed substrate concentration. In partial competitive
inhibition, the resulting curve reaches a plateau at a limiting velocity, and the reaction
rate shows no tendency to approach zero. In contrast, both one-site and two-site types of
pure competitive inhibition will give plots that indicate that reaction velocity approaches
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Figure 18: HlyA inhibition with respect to myristoyl-ACP. Evaluation of the kinetic
parameters of myristoyl-ACP was done at a fixed proHlyA concentration of 2 uM in the
presence of the following concentrations o f the product HlyA: V, 2.3 |iM ; A, 1.5 |iM; □,
0.3 pM; and o, 0 pM. Velocity (v) was in identical arbitrary units in all half-reciprocal
plots. The inset shows the double reciprocal plot slopes, Km*pf>/V max*pp, versus the
corresponding [HlyA] (pM).
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zero upon sufficiently increasing [I]. Such a plot o f the data from Figure 18 showed no

leveling off o f the reaction velocity as [I] increased so the inhibition was not partial
competitive inhibition (Figure 20A). Furthermore, as shown in the inset in Figure 18, the
replot of double reciprocal plot slopes versus [I] was parabolic; this is diagnostic of two
site, competitive inhibition (87). Similar plots of data describing one-site pure
competitive or partial competitive systems would, in comparison, yield linear and
hyperbolic replots, respectively. Dixon plots (reciprocal velocity values at fixed [S]
against [I]) and plots of Kmappversus [1] were both parabolic (not shown) as would be
expected in two-site, pure competitive inhibition (87).
When different fixed amounts of the product HlyA were added to reactions where
proHlyA concentration was varied, a primary plot pattern like that described above for
HlyA inhibition with respect to myristoyl-ACP was observed. HlyA inhibited with
respect to proHlyA as shown in Figure 19 where the primary half-reciprocal plots at
different HlyA concentrations formed parallel lines. The corresponding doublereciprocal plots showed increasing slopes with increasing inhibitor concentration while
all plots intersected on the 1/v axis (not shown). These patterns indicated competitive
inhibition. As mentioned above, there are several types of competitive inhibition, and all
have the same primary plot pattern. A secondary plot of initial velocity versus [HlyA] at
fixed [S] showed a tendency for the velocity to plateau at higher concentrations of HlyA
as shown in Figure 20B. This was in contrast to the results from above shown in Figure
20A where a continuously decreasing velocity was observed as inhibitor concentration
increased. This finding indicated partial competitive inhibition. In confirmation of
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Figure 19: HlyA inhibition with respect to proHlyA. Evaluation of the kinetic
parameters of proHlyA was done at a fixed myristoyl-ACP concentration of 1 pM in the
presence of the following concentrations of the product HlyA: V, 2.7 pM; A, 1.3 pM; □,
0.6; and o, 0.06S pM. Velocity (v) was in identical arbitrary units in all half-reciprocal
plots. The inset shows the double reciprocal plot slopes, Km*p,7Vmaxapp, versus the
corresponding [HlyA] (pM).
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Figure 20: Plots of initial velocities at fixed [S] in the presence of product, [HlyA] (pM )
with myristoyl-ACP (A) or proHlyA (B) as the variable substrates. Initial reaction
velocities are given in dpm. In (A), in the presence of different concentrations of HlyA
(pM), reaction velocities were determined at the following different [myristoyl-ACP]: A,
3 pM; □, I pM; and o, 0.5 pM. [ProHlyA] was fixed at 2 pM. In (B), in the presence of
different concentrations o f HlyA (pM)> reaction velocities were determined at the
following different [proHlyA]: o, 3 pM; □, 2 pM; and A, 1 pM. [Myristoyl-ACP] was
fixed at 1 pM.
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partial competitive inhibition (also called hyperbolic inhibition), the replot of double
reciprocal plot slopes versus [HlyA] was hyperbolic (Figure 19 inset) (88). Unlike the
situation with simple linear inhibition, Kj cannot be obtained from the intercept of the
replot, but the equation for partial competitive inhibition can be converted into a linear
relationship (89). In this way, a Kj of 4.3 pM HlyA was obtained from a linear plot
(Figure 21) of 1/A slope against l/[HlyA].
The partial competitive inhibition seen when [HlyA] was varied with respect to
proHlyA may be regarded as a variant of mixed-type inhibition (90); the basis for this
will be discussed later. The product inhibitions for the HlyC catalyzed reaction are
summarized in Table 7. At fixed, nonsaturating concentrations of proHlyA or myristoylACP respectively, ACPSH inhibitions with respect to myristoyl-ACP or proHlyA were
each mixed-type inhibition. HlyA inhibition with respect to myristoyl-ACP, at fixed,
nonsaturating concentrations o f proHlyA, gave a pattern of competitive inhibition. A
different pattern was obtained for HlyA inhibition with respect to proHlyA at fixed
nonsaturating concentration o f myristoyl-ACP; a pattern consistent with a form of mixedtype inhibition was observed. The product inhibition patterns o f the acyltransferase
reaction shown in Table 6 conformed to an uni uni iso uni uni ping pong kinetic
mechanism with isomerization o f the F form of the enzyme (91).
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Figure 21: Determination of the Kj for HlyA inhibition with respect to proHlyA at fixed
[myristoyl-ACP]. The relationship between Km*pp/V 1IUX*pp (double-reciprocal plot slopes
or half-reciprocal plot intercepts) and different [HlyA] provides -Ki on the x intercept
when the relationship is linear (S9). Data are from Fig. 19. The linear correlation
coefficient was I.
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Table 6: PRODUCT INHIBITION PATTERNS*

variable substrate

product

fixed substrateb

inhibition pattern6

myristoyl-ACP

ACPSH

proHlyA

mixed-type

proHlyA

ACPSH

myristoyl-ACP

mixed-type

myristoyl-ACP

HlyA

proHlyA

competitive

proHlyA

HlyA

myristoyl-ACP

mixed-type

*The assay procedure and reaction conditions are given in Experimental
Procedures. bNonsaturating concentrations of fixed substrates were used, inhibition
pattern notations are those described by Segel (91).
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Chemical Mechanism of HlvC

Chemical Modification o f HlvC
As discussed earlier, HlyC appears to be a unique acyltransferase resembling no
other known acyltransferases. However, it has been demonstrated that some RTX C
proteins can acylate pro-RTX toxins from different organisms, indicating a similar mode
of action for the various RTX C acyltransferases. To elucidate the chemical mechanism
of this unique enzyme, the deduced amino acid sequences o f 13 different RTX C proteins
were compared. The sequence alignment shown in Figure 22 reveals a high degree of
identity, with the majority of homology concentrated in the N-terminal region. Possibly,
the N-terminal region of HlyC may be involved in the acyl transfer reaction; whereas, the
unique C-terminal regions of the various acyltransferases may be involved in recognition
of the diverse protoxins. Out o f 170 residues in HlyC, 37 are totally conserved in the 13
RTX C gene products (Figure 22). O f particular interest to us were those residues that
could covalently bear an acyl group since HlyC forms an acyl-enzyme intermediate in the
presence of its first bound substrate, acyl-ACP. To investigate the chemical mechanism
for the acyl transfer reaction, HlyC was covalently modified by a number of chemical
reagents. The reactions for the various chemical modification reagents used in this study
are shown in Figure 23.
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HLYC_ECOLI
HLC1_EC0LI
HLC2_EC0LI
HLYCEH
RT1C_ACTPL
RT2 C_ACTPL
RT3C_ACTPL
HLYC_ACTAC
HLC1_PASHA
HLC3_PASHA
HLCB_PASHA
HLYC_PASSP
CYAC

30
VLPA
PLBRNlPVSL
VLPA
pl I rnI p v s l
VLPA
pl I rnI p v s l
plbck I p l s v
pl I rk J p l s l
VLPA
pmI rn I s v s l LMK VIPA
pl I ke I s i s l
pl I rn I s l s l
sl I ke I s c e l
VI PA
sl I ke I sc k l LAC VIPA
pl I ke I s c e l
VIPA
pl I re I s c e l
VIPA
TLAF
pmI rd I pvhl

HLYC_ECOLI
HLC1_EC0LI
HLC2_EC0LI
HLYCEH
RT1C_ACTPL
RT2C_ACTPL
RT3C_ACTPL
HLYC_ACTAC
HLC1_PASHA
HLC3_PASHA
HLCB_PASHA
HLYC_PAS S P
CYAC

NLSLEN
NLSLEN
NLSLEN
SLDLEC VK|
NLNLEN
KLTLES
NLTLTN VK
nlslenT
DLNLET|VK
DLNLET VK
DLNLEN VK
DLSLET VK
LMDADT LS

INDV
LDDV.

VMAPS

Figure 22: Partial amino acid sequence alignment of 13 RTX toxin C gene products.
HLYC_ECOLI, £. coli HlyC, pHlyl52 encoded, acession no. p06736; HLCl_ECOLI, E.
coli strain J96 HlyC, chromosome encoded, accession no. p09984; HLC2_ECOLI, E. coli
strain 2001 HlyC, chromosome encoded, accesion no. p09985; HLYCEH, E. coli
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HLYC_ECOLI
HLC1_EC0LI
HLC2_EC0LI
HLYCEH
RT1C_ACTPL
RT2C_ACTPL
RT3C_ACTPL
HLY C_ACTAC
HLC1_PASHA
HLC3_PASHA
HLCB_PASHA
HLYC_PAS S P
CYAC

HLYC_ECOLI
HLC1_EC0LI
HLC2_EC0LI
HLYCEH
R T 1C_ACTPL
RT2C_ACTPL
RT 3C_ACTPL
HLYC_ACTAC
HLC1_PASHA
HLC3_PASHA
HLCB_PASHA
HLYC_PASSP
CYAC

D
V
D
D
D
D
D
D
D
D
D
D
D

I.
I
I
I
I
I
I
I

I

137
GKVSEFH GK
GKVSEFH GK
GKVSEFH GK
GKIAEFH GG
GKISEFH GK
GKIIYLK GK
AKIIHVQ GQ
GKITEFH GK
GKIAYFK GK
GKITYFK GK
GKISYFK GK
GKIAYFK GN
ARVKEYR RA

108
YKYMR
YKYMR
- -GA YKYMR
--ME YKYMR
YKHMR
YKHMR
-NTBYRYMR
--YV^YKHMR
YKKMC
YKKMC
YKKMC
IKNVS
dnraBr r a l a

118
KKFBDELFRA
KKF DELFRA
KKF DELFLA
KKY YELFRP
DNF NELFRA
QRF YDIGRA
KKF NEVFRA
KSF YDLFRS
QKY DMIVRS
QKY DMIVRA
QKY DMIVRS
E-I DYSRQI
ERH DSVGRS

147
IDKQLANKIF
IDKQLANKIF
IDKHLANKIF
IDKKLASKIF
IDKKLASKIF
ITKKVAEKTF
INKFTAKKLI
VDKQLANKIF
LDKKTAKKRF
LDKKTAKERF
LDKKTAKKRF
LDKKTAKKRF
LDAAATRAQL

157
ITE
ITE
ITE
MSE
MSE
ITA
IQV
INE
ATA
ATA
ATA
GAA
IAG

KQ
KQ
KQ
RQ
QQ
LQ
QQ
QQ
DT
DI
DT
DT
DR

HHE
HHE
HHE
HHE
HFE
EQE
QEE
HFE
QEE
QEE
QEE
QER
HAE

127
IRVDPKTH-V
IRVDPKTH-V
IRVDPKTH-V
IRLDESSK-T
IRVDPDSR-V
IRIYPSKKDT
IRVYPGST-E
IRVYKGSS-E
IRFYPKQKEL
IRFYPKQKEL
IRFQPNQKSV
YTLLSKTKRT
LRVRRGGDT-

Figure 22 (continued): 0157:H7 strain EDL 933 HlyC, plasmid encoded, translation of
nucleotide sequence accesion no. x8089l; RTIC ACTPL, A. pleuropnenmoniae ApxIC, accesion no. p55132; RT2C_ACTPL, A. pleuropneumoniae Apx-IIC, accesion no.
p i5376; RT3C_ACTPL, A. pleuropneumoniae, Apx-IIIC, accession no. q04474;
HLYC_ACTAC, A. actinomycetemcomitans LktC, accession no. p 16461;
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Figure 22 (continued): HLC I P ASHA, P. haemolytica serotype A1 LktC, accession no.
pl6533; HLC3_PASHA, P. haemolytica sertoype T3 LktC, accession no. p55120;
HLCB_PASHA, P. haemolytica serotype A11 LktC, accession no. pSS121;
HLYC_PASSP, P. haemolytica-Wke sp. LktC, accession no. p55124; CYAC, B. pertussis
CyaC, translation o f nucleotide sequence accession no. mS7286. Nonconserved amino
acids are shown in uppercase letters; conserved residues are shown in bold uppercase
letters. Amino acid residues that are identical in all 13 RTX C proteins are shaded. The
sequence aligment was done using the Hibio Prosis protein analysis software by Hitachi.
Amino acid sequence number refers to positions in the E. coli HlyC encoded by plasmid
pHlyl52.
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The RTX acyltransferases all contain a single conserved Cys residue, Cys 58 in
HlyC. NEM, which reacts specifically with sulfhydryl groups (78), did not affect enzyme
activity (Table 7). Since the nature of the environment surrounding the reactive group
can effect its reactivity with various chemical reagents, a second more hydrophobic
sulfhydryl-specific modifying reagent, PCMB (92), was also tested as an inhibitor for the
acyltransferase. Again, there was no decrease in enzyme activity (Table 7), suggesting
a -SH group is not necessary for catalysis. HlyC was also insensitive to PMSF or
AEBSF (Table 7), which could potentially modify one or more of the three conserved
serines; residues 20, 58, and 76, suggesting that the enzyme is not a serine-dependent
acyltransferase.
HlyC contains one conserved His at position 23, which could be involved in the
enzymatic transfer of an acyl chain. His could function as a base deprotonating a
nucleophilic residue accepting the acyl chain or possibly serve as the acyl acceptor,
although an acyl-imidazole enzyme intermediate has never been reported previously.
HlyC was rapidly inactivated by DEPC at pH 6.0 (Table 7 and Figure 24). At this pH,
the reagent is highly specific for histidine residues producing N-carbethoxyhistidine
(Figure 23 reaction 4), while at pH 8.0 the reagent may modify cysteine, tyrosine, and
lysine residues (79). HlyC treated with 1 mM DEPC at pH 6.0 retained 16±1%
acyltransferase activity as compared to 68±0% remaining activity at pH 8.0 suggesting a
specificity for histidine (Table 7).
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Table 7: IN H IB ITIO N OF HLYC ACYLTRANSFERASE ACTIVITY BY
CHEMICAL MODIFIERS

Modifier
NEM

[Modifier]
(mM)
1.0

Reaction Conditions*
0.1 M KP04 (pH 7.0), 15 min

% Activity
Remaining1*
100±10

PCMB

1.0

20 mM Mes (pH 6.0), 10 min

117±1

PMSF

1.0

25 mM Hepes (pH 8.0), 10 min

95±10

AEBSF

1.0

25 mM Hepes (pH 8.0), 10 min

126±0

DEPC

1.0

0.1 M KPO4 (pH 6.0), 10 min

16±1

DEPC

1.0

0.1 M KPO4 (pH 8.0), 10 min

68±0

TNM

1.5

0.05 M Tris (pH 6.0), 30 min

81±1

TNM

1.5

0.05 M Tris (pH 8.0), 30 min

20±1

NAI

1.3

50 mM Hepes (pH 7.5), 30 min

83±2

PG

5.0

25 mM Hepes (pH 8.0), 1 h

10±2

aAll chemical modification reactions were performed at 25 °C. bActivity is the % of the
control reaction without modifier. As described in the Materials and Methods a separate
control was completed for each modification reaction. On average, control reactions
containing 10 gg of HlyC gave 35.0±2.5 pmoles o f acyl group transferred/assay.
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Figure 24: Inhibition of HlyC acyltransferase activity by protein modification reagents.
HlyC was incubated with increasing concentration of (□) DEPC, (o) TNM, or (A) PG.
Chemical modification reactions were performed as described in the Materials and
Methods with each reaction having its own control not exposed to the chemical modifier.
Control activities for the DEPC, TNM, and PG modification experiments were 29.0±3.0,
40.0±1.0, and 37.0±1.0 pmoles acyl group transferred/assay, respectively. Assays
contained 10 pg HlyC.
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Treatment of DEPC modified HlyC with 100 mM NH 2OH (pH 7.0) (Figure 25)
resulted in a time dependent re-activation of the enzyme activity with 87±1%
acyltransferase activity after 4 h, indicating that inactivation was not due to lysine,
tyrosine, or sulfhydryl modification (79). DEPC modification of cysteine or lysine
residues is not reversed by NH 2OH treatment and modified tyrosines are reversed at a
much slower rate (79). Incomplete reactivation of the enyzme could be attributed to
either modification of lysyl residues which are not affected by hydroxylamine treatment;
but are essential for HlyC function, or possibly due to the formation of a disubstituted
histidyl derivative that is not regenerated by hydroxylamine (79). Modification of
hisitidine by DEPC was confirmed by difference spectroscopy of DEPC modified and
native HlyC, showing an absorption maximum o f242 nm characteristic for Ncarbethoxyhistidine with no significant decrease in abosrbance at 278 nm characteristic
of ethoxyformylation of tyrosine (Figure 26) (79). The inactivation of the acyltransferase
by DEPC followed pseudo first-order kinetics and correlated with the formation of Ncarbeothoxyhistidine as shown by increasing absorbance at 242 nm over time (Figure
27).
HlyC contains two conserved tyrosines, Tyr 70 and Tyr 150, that could serve as
acyl acceptors forming oxygen esters. At pH 8.0, TNM can specifically modify tyrosine
residues producing 3-nitrotyrosine (Figure 23 reaction 5); whereas, at a pH 6.0 the
reagent oxidizes sulfhydryl groups (93, 94, 95). HlyC was inactivated by TNM at pH 8.0
(Table 7 and Figure 24) with only 20±1% activity remaining at pH 8.0 as compared to
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Figure 25: Reversibility of DEPC modification of HlyC. HlyC was incubated with 2 mM
DEPC for 10 min at 25 °C until 13% acyltransferase activity remained followed by
addition of NH 2OH (pH 7.0) to a concentration of 100 mM. At various time points,
aliquots containing 10 pg of HlyC were removed and acyltransferase activity measured.
Activity was expressed as the percentage o f a control reaction not exposed to DEPC but
incubated with 100 mM NH 2OH (pH 7.0) for 4 hrs. Control HlyC (10 pg) activity was
50.0±1.0 pmoles acyl group transferred/assay.
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Figure 26: U V absorbance difference spectra demonstrating the effect of DEPC
modification o f HlyC. A 1.0 mg/mL S-tag-HlyC solution in a double sectored cuvette
was modified with 1 mM DEPC in 0.1 M KPO4 (pH 6.0) at 25 ?C as described in
Materials and Methods. Spectra were recorded at 1,2 ,4 ,6 ,1 0 , 15, and 20 min intervals.
The difference spectrum exhibits an absorbance peak at 242 nm that increases over time.
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Figure 27: Correlation between the rate of DEPC modification (□) and loss of HlyC
acyltransferase actvity (o). S-tag-FflyC in 0.1 M KPO4 (pH 6.0) was treated with 1 mM
DEPC at 25 °C and at various time intervals 10 pg aliquots of HlyC were removed and
assayed for activity (o). Activity is expressed as the percentage of a control reaction
(38.0±2.0 pmoles acyl group transferred/assay) containing 10 pg HlyC that was not
exposed to DEPC. For absorbance studies, S-tag-HlyC modified under the same
conditions was monitored for change in the absorbance at 242 nm.
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81±1% activity remaining at pH 6.0 indicating that inactivation by TNM is not due to
thiol oxidation. Modification of tryptophan residues was not considered likely since this
reaction takes place at pH 9.0 or greater (96, 97). Comparison of the modified and
unmodified HlyC spectra showed an absoprtion maximum at 428 nm (Figure 28),
consistent with the formation of nitrated tyrosine (94). TNM inactivation followed
pseudo first-order kinetics and this decrease correlated with the formation of 3nitrotyrosine as shown by the increase in absorbance at 428 nm over time (Figure 29).
TNM may induce the precipitation of some proteins through protein crosslinking
resulting in loss of enzyme activity that is unrelated to tyrosine nitration (98, 99).
Possible cross linking of HlyC was tested by treating the enzyme with TNM followed by
SDS-PAGE and western blotting using the S-protein alkaline phosphatase conjugate.
There was no evidence o f dimer, trimer, or large aggregate formation indicating that
inactivation of HlyC was not due to protein cross linking (data not shown).
Like TNM, N-acetylimidazole under mild conditions reacts specifically with
tyrosyl groups o f proteins (100). Unlike TNM, the reaction directly effects the -O H
group of the residue forming O-acetyltyrosine (Figure 23 reaction 6). HlyC activity was
not affected by modification with N-acetylimidazole; 83±2% of acyltransferase activity
remained after treatment with 1.3 mM of the reagent (Table 7). Acetylation of tyrosyl
residues within HlyC was confirmed by a decrease in the absorbance at 278 nm (data not
shown). The small decrease in activity probably stems from modification of lysyl
residues (100). Acetylation of tyrosine residues had no effect on acyltransferase activity
but, nitration of tyrosines almost completely inactivated the enzyme, suggesting that a
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Figure 28: UV-Vis Spectra of TNM modified (-----) and unmodified (— ) HlyC. An 2.72
mg/mL S-tag-HlyC solution in 0.05 M Tris pH 8.0 was modified with a 50-fold molar
excess o f TNM (6.0 mM) for 30 minutes at 25 °C in a double sectored cuvette as
described in Materials and Methods.
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Figure 29: Correlation between the rate of TNM modification (□) and loss o f HlyC
acyltransferase actvity (o). S-tag-HlyC in 0.05 M Tris (pH 8.0) was treated with 1 mM
TNM at 25 °C and at various time intervals 10 pg aliquots of HlyC were removed and
assayed for activity (o). Activity is expressed as the percentage of a control reaction
containing 10 pg of HlyC (45.0±0 pmoles acyl group transferred/min) that was not
exposed to TNM. For absorbance studies, S-tag-HlyC modified under the same
conditions was monitored for change in the absorbance at 428 nm.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

89
tyrosine residue is important, but its functional -O H group is not.
Phenylglyoxal (PG) is relatively specific for arginine at neutrality giving
derivatives containing two PG moieties per guanidino group (Figure 23 reaction 7) {101,
102). Since HlyC contains two conserved arginines, residues 24 and 87, (Figure 22) the
effects of PG on enzyme activity was tested. HlyC was sensitive to increasing
concentrations of the reagent (Figure 24) with only 10±2 % of the control activity
remaining following treatment with S mM PG, implicating an essential arginine residue.
The presence of substrate during chemical modification can be used to selectively
prevent modification o f residues that are somehow protected upon substrate binding.
This protection is usually explained as the residue being located within the active site;
however, protection may occur as a result of structural changes following substrate
binding leading to a change in the accessibility of the residue to the chemical modifier
{103). Protection against TNM*, DEPC-, and PG-induced inactivation of HlyC was
examined using acyl-ACP and ACPSH. Acyl-ACP consistently offered significant
protection from the various chemical modifiers, whereas ACPSH was unable to protect
HlyC from TNM and DEPC modification, and offered little protection from PG (Figure
30).

Characterization o f HlvC Mutants
Chemical modification of HlyC provided information for possible residues
essential for the catalytic mechanism of the enzyme. In order, to examine the function of
specific conserved residues and possibly corroborate the chemical findings, site-directed
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Figure 30: Protection of HlyC activity against DEPC, TNM, or PG inactivation by either
acyl-ACP or ACPSH. Enzyme was modified with either 2 mM DEPC, 50-fold molar
excess (0.22 mM) of TNM , or 5 mM PG. Prior to the addition of the chemical modifier,
- 2 pM HlyC was incubated with either 2 pM unlabeled myristoyl-ACP or ACPSH.
After modification, the unlabeled ACPs were removed by 70% (NH 4 >2S0 4 precipitation
at pH 7.0 and the enzyme assayed using [I4C]myristoyl-ACP as described in Materials
and Methods.
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mutagenesis studies o f the acyltransferase were employed. Residues that were
conserved within the 13 different RTX toxin acyltransferases (Figure 22) were
individually mutagenized, the mutation confirmed by DNA sequencing (data not shown),
and the corresponding HlyC expressed and purified as a His6-S-tag fusion protein. The
expression of all HlyC mutants (data not shown) was identical to native HlyC (Figure 3).
The acyltransferase activity was examined for mutant HlyCs isolated from inclusion
bodies in HED 6 M urea followed by slow renaturation of the enzyme by dialysis
(refolded HlyC) or for HlyC in which the urea concentration was lowered by dilution
with HED buffer (quickly diluted HlyC). The initial activity studies for refolded and
quickly diluted HlyCs are summarized in Table 8. Activites ranging from 0-10% of the
native activity were indiscernible from 0 using the HlyC assay system presented, a
common problem in assessing activities of mutant proteins {104).
Mutation o f the conserved and only cysteine (Cys 57) of HlyC to an alanine
showed the same level of acyltransferase activity as did wild-type enzyme. Changing
conserved serines 58 and 76 o f HlyC to alanines, showed little o r no decrease in activity;
however, the S20A mutant retained only -30% wild-type activity. Interestingly, the
S76A mutant experienced ~30% increase in activity resulting in native acyltransferase
activity upon slow renaturation o f the enzyme as compared to the quick diluted HlyC.
Obviously, Ser 20 and 76 have some part in wild-type acyltransferase function.
HlyC was very sensitive to DEPC and TNM, leading to acetylation o f histidine
residues and nitration o f tyrosine residues respectively. Mutation of the conserved
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Table 8: ACYLTRANSFERASE ACTIVITES OF SINGLE-SITE MUTANT HLYCS
% of Wild-Type Acyltransferase Activity*
Mutation

Quick Diluted HlyC

Refolded HlyC

G11A

14.1*0.1

23.2*0.4

G85A

0.0*0.4

3.6*04

H23A

7.9±0.3

4.4*0.1

H23S

6.6±0.4

5.6*04

H23C

11.7*1.5

3.5*09

R24A

66.7*1.8

63.8*0.2

R87A

17.7*0.6

86.1*1.7

S20A

36.3*0.3

31.2*0.3

S58A

78.1*0.4

75.3*1.3

S76A

63.2*7.3

94.1*4.0

E67A

75.6*0.3

107.0*2.1

D86A

64.3±0.1

70.4*0.2

Y70G

10.0±1.1

11.8*0.1

Y70F

74.5±5.2

104.0*2.5

Y150G

21.1*1.2

44.3*0.7

Y150F

91.6*1.7

85.5*4.3

C57A

90.0*0.7

95.6*2.5

'Acyltransferase activities were measured as described in Materials and Methods. Slowly
refolded wild-type HlyC activity was 71.0*2.3 picomoles acyl group transferred /5 pg
enzyme. Wild-type quick dilution HlyC activity was 47.0*2.4 picomoles acyl group
transferred/5 pg enzyme. Each % is the average of at least 3 determinations enzyme *
standard deviation.
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histidine and the two conserved tyrosines significantly effected acyltransferase activity.
Changing conserved His 23 to an alanine led to total inactivation o f the acyltransferase.
Mutation o f conserved Tyr 70 and Tyr ISO to glycines resulted in inactivation of the
acyltransferase for the Y70G mutant and 40% of the wild-type activity for the refolded
Y1S0G mutant. Like the S76A mutant, the Y1S0G HlyC showed a difference in
acyltransferase activity between the quickly diluted and refolded enzyme with a 20%
increase upon slowly refolding the protein.
Mutation of conserved arginine residues 24 and 87 to alanines affected HlyC
activity. The R24A HlyC mutant possessed ~65% of the wild-type activity for both the
quickly diluted and refolded HlyCs; whereas, the R87A mutant demonstrated a
significant difference between the two methods of renaturing HlyC. Quickly diluted
R87A HlyC retained only ~20% o f the wild-type activity, but upon slowly refolding it
functioned at wild-type levels with ~90% activity. Becuase both R24A and R87A HlyCs
possessed significant acyltransferase activities upon refolding, these mutants were tested
for sensitivity to PG. Both HlyCs were still inhibited by PG to the same extent as the
inhibition seen with the wild-type enzyme (data not shown), suggesting that both Arg 87
and Arg 24 could be the potential targets for PG modification as well as other arginines
within HlyC.
No chemical modifications o f HlyC were done that would modify acidic residues,
but two mutants were made changing two conserved acidic residues to alanines.
Changing Glu 67 to an alanine had no effect on enzyme activity. Changing Asp 86 to an
alanine resulted in a 30-40% decrease in acyltransferase activity. These data suggest that
neither residue is critical for HlyC activity, but Asp 86 does seem necessary for wild-type
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acyltransferase function. Mutation of the two conserved glycines, Gly 11 and 85, to
alanines were detrimental to acyltransferase activity resulting in 14-20% activity for
mutant G11A and no activity for the G85A mutant.
To examine further the function of residues His 23, Tyr 70, and Tyr 150 these
residues were mutated. Tyrosines 70 and 150 were mutated to phenylalanine. These
HlyCs, Y70F and Y150F, functioned at native levels. Furthermore, both mutants were
inactivated like the native enzyme by TNM (data not shown) therefore both Tyr 70 and
150 are potential targets for TNM along with other tyrosines in the enzyme. His 23 was
also mutated to a serine and a cysteine residue, both of which could bear an acyl group.
Like the H23A mutant, the H23S and H23C mutant acyltransferases showed no activity.
Mutant HlyCs were monitored for the formation of [ t4C]acyl-enzyme
intermediate and products resulting from chemcial cross-linking reactions with [14C]
myristoyl-ACP. The data are summarized in Figure 31, Figure 32, and Table 9.
Essentially, any mutant HlyC that was able to function at or near wild-type levels
produced [14C]acyl-enzyme intermediate and cross-linked with [l4C]myristoyl-ACP like
the native enzyme (Refer to Figure 12). Mutant HlyCs functioning in this manner
included the following: R24A, C57A, S58A, E67A, Y70F, S76A, D86A, R87A, and
Y150F. In some cases, single-site mutations of HlyC produced acyltransferases able to
cross-link to acyl-ACP, but unable to produce acyl-HlyC intermediate. These mutations
include H23A, H23C, H23S, S20A, G11A, Y70G, and Y150G. H23A, H23S, H23C, and
S20A HlyCs all cross-linked at normal levels, while the G11A, Y70G, and Y150G
mutants cross-linked at much lower levels as compared to the wild-type control. Only
the G85A mutant resulted in a loss of heterodimer and acyl-intermediate formation. No

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

95

Acyl-HlyC Dimer

[wClacyl-ACP

|£g§aAcyl-HlyC Dimer

|wC|acyl-ACP

l,4Clacyl-ACP

Figure 31: Fluorographic demonstration of [l4C]acyl-HlyC enzyme intermediate
formation for mutant HlyCs. All reactions contained 2.5 pM [uC]myristoyl-ACP
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Figure 31 (continued): A reaction containing only [MC]myristoyl-ACP is shown in the
top fluorograph (negative control). When present in reaction, the particular HlyC is
given above its respective lane. Reactions contained SO pM of enzyme. Each
fluorograph respresents a separate experiment and contains its own native control to
which the mutant HlyCs were compared. Reactions were carried out as described in
Materials and Methods.
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Heterodimer

[wC|acyl-ACP

Heterodimer

|MC|acyl-ACP

lMClacyl-ACP

Figure 32: Fluorographic demonstration o f Acyl-ACP-HlyC heterodimer formation upon
chemical cross-linking with [I4C]myristoyl-ACP and mutant HlyCs in the presence of
DMS
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Figure 32 (continued): All reactions contained 2 pM [l4C]myristoyl-ACP and DMS.
A reaction with 2 pM [,4C]myristoyl-ACP alone in the presence of DMS (negative
control) is shown in the top fluorograph. When present in reaction, the particular HlyC is
given above its respective lane. Reactions contained 10 pg (4.S pM) of enzyme. Each
fluorograph represents a separate experiment and contains its own native control to which
the mutant HlyCs were compared. Reactions were carried out as described in Materials
and Methods.
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Table 9: SUMMARY OF ACYL-ENZYME INTERMEDIATE AND ACYL-ACPHLYC HETERODIMER FORMATION OF HLYC MUTANTS'
Mutation

Acyl-Enzyme Formation

G11A

Not Detectable

Acyl-ACP-HlyC
Heterodimer Formation
Low

G85A

Not Detectable

Not Detectable

H23A

Not Detectable

Normal

H23S

Not Detectable

Normal

H23C

Not Detectable

Normal

R24A

Intermediate

Intermediate

R87A

Low

Normal

S20A

Not Detectable

Normal

S58A

Normal

Normal

S76A

Normal

Normal

E67A

Normal

Normal

D86A

Intermediate

Intermediate

Y70G

Not Detectable

Low

Y70F

Normal

Normal

Y150G

Not Detectable

Low

Y150F

Normal

Normal

C57A

Normal

Normal

'Fluorographs from Figure 31 and 32 were scanned followed by densitometry
measurements using the UnScan It Software. Densities of bands produced by mutant
HlyCs were compared to bands produced by the native HlyC control on each fluorograph.
Intensities o f the bands were ranked as either normal, intermediate, low, or not
detectable.
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mutation produced an enzyme capable o f acyl intermediate formation production with the
lack of heterodimer production. For mutations S58A, S76A, R24A, E67A, Y70F, and
Y1S0F an additional band was seen in acyl-enzyme formation experiments at the size
expected for an acyl-HlyC dimer (Figure 31), whereas, wild-type enzyme never produced
acyl-enyzme in the dimer form in any o f the fluorographs.
The kinetic parameters for myristoyl-ACP and proHlyA were determined for
His6-S-tag-HlyC and mutant fusion proteins with detectable acyltransferase activity.
Myristoyl-ACP had a K m ^of 0.61±0.1 pM, and a Vnux*P!>of 14.0±0.5 pmoles of acyl
group transferred/min with proHlyA held constant at 2 pM (Table 10). ProHlyA had a
Km*pp of 2.19±0.17 pM and a Vm«*pp o f 15.2±2.7 pmoles acyl group transferred/min with
myristoyl-ACP held constant at 1 pM (Table 11). There was no significant difference
between the Kmappvalues for myristoyl-ACP or proHlyA for the S-tag and His«-S-tag
HlyCs. Although the

value for myristoyl-ACP and proHlyA increased for the

Hist-S-tag HlyC enzyme, the increase in acyltransferase activity was due to the improved
quality o f the proHlyA preparations rather than differences in the specific activity o f the
two fusion proteins.
For the majority of the single-site mutations there was no significant change in the
value o f Km*" or Vm,.<ppfor either myristoyl-ACP (Table 10) or proHlyA (Table 11).
This was not too surprising since through mutagenesis studies such as these it has become
apparent that most proteins can tolerate single residue substitutions quite well (104). O f
course the most interesting mutations were those that resulted in complete loss of
function; G l 1A, H23A, H23S, H23C, Y70G, and G85A. There were, however, two
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Table 10: KINETIC PARAMETERS OF MYRISTOYL-ACP FOR NATIVE
AND M UTANT M S6-S-TAG-HLYCS*
Mutation

V

«PP

% of native Km*pp

v» max*pp

% of native V max*pp

None

0.61±0.1

100

14.0±0.5

100

G11A

NDb

ND

ND

ND

G8SA

ND

ND

ND

ND

H23A

ND

ND

ND

ND

H23S

ND

ND

ND

ND

H23C

ND

ND

ND

ND

R24A

0.32±0.02

52

6.2±0.1

44

R87A

0.36±0.10

59

7.0±0.3

50

S20A

0.40*0.10

66

1.8±0.7

13

S58A

0.26±0.01

43

5.6±0.2

40

S76A

0.30±0.01

49

7.6±0.1

54

E67A

0.77±0.01

126

17.0±0.7

121

D86A

0.29±0.01

48

9.2±0.1

66

Y70G

ND

ND

ND

ND

Y70F

0.80±0.10

131

11.8±0.4

84

Y150G

0.97±0.10

159

4.2±0.2

30

Y150F

0.65*0.10

107

14.2±0.5

101

C57A

0.62*0.01

102

13.7±0.6

98

*Km*pp in pM, and Vimx*pp is pmol incorporaied/min. Kinetic parameters are apparent
values for the particular conditions given including the concentration of the fixed
substrate, proHlyA, which was 2pM. bKinetic parameters of mutant HlyCs without
sufficient activity were not determined (ND).
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Table 11: KINETIC PARAMETERS OF PROHLYA FOR N A TIVE AND
M UTANT HISe-S-TAG-HLYCS*
Mutation

V

«PP

% of native

v▼max*PP

% o f native V imxipp

N n

None

2.19±0.17

100

15.2 ±2.7

100

G11A

NDb

ND

ND

ND

G8SA

ND

ND

ND

ND

H23A

ND

ND

ND

ND

H23S

ND

ND

ND

ND

H23C

ND

ND

ND

ND

R24A

2.12±0.13

97

10.6±0.3

70

R87A

2.61 ±0.26

119

U.6±0.6

76

S20A

1.31±0.10

60

2.0±0.1

13

SS8A

1.43±0.15

65

7.13±0.3

47

S76A

2.39±0.20

109

12.5±0.5

82

E67A

1.89±0.13

86

15.0±0.5

99

D86A

1.78±0.10

81

10.5±0.3

69

Y70G

ND

ND

ND

ND

Y70F

1.89±0.13

86

15.0±0.5

99

Y150G

1.45±0.23

66

3.14±0.2

21

Y150F

1.71±0.06

78

12.6±0.2

83

C57A

2.20±0.17

100

14.6±0.6

96

'Km** in (iM, and V ~ .*pp is pmol incorporated/min. Kinetic parameters are apparent
values for the particular conditions given including the concentration of the fixed
substrate, myristoyl-ACP, which was IpM . ‘Kinetic parameters o f mutant HlyCs without
sufficient activity were not determined (ND).
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mutations that resulted in significant changes in the VmaXt,>pvalues for both substrates.
Both the Y1S0G and S20A HlyCs produced Vm„ a,’p values for myristoyl-ACP and
proHlyA that were significantly reduced compared to the wild-type enzyme.
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CHAPTER 4
DISCUSSION

All the proteins involved in rendering proHlyA toxic were highly purified except
the proHlyA which was >90% pure; both intracellular proHlyA and secreted proHlyA
served as substrates in the reaction. It is unlikely that an unrecognized HlyC-dependent
acyltransferase activity could be present as a contaminant in each of these disparate
proHlyA preparations. The role of HlyC as the acyltransferase was confirmed (15,105)
by showing that the purified fusion protein was the single factor necessary in bringing
about toxin formation in the presence of acyl-ACP and proHlyA. Furthermore, although
HlyC and proHlyA may be produced in similar amounts in vivo, the catalysis o f the
internal protein fatty acylation was a typical enzyme-substrate relationship. Catalysis
ensued with less than stoichiometric amounts of HlyC relative to proHlyA and fatty acyl
groups transferred. The specific activity of the enzyme isolated from the soluble portion
of the cell lysate was approximately 300 times greater than the best renaturation achieved
from inclusion bodies, and it had a roughly estimated turnover number of 4,450
moles/min, a respectable enzymatic activity. The cell soluble extract HlyC would likely
be more representative of the in vivo enzyme catalyzing toxin activation than that from
inclusion bodies. HlyC extracted from inclusion bodies was, however, much purer.
Aggregation in inclusion bodies has been shown to be protein-specific, and, thus
relatively pure proteins are extracted from the inclusion body state (106).
The acyltransferase assay was highly reproducible, quantifiable, and, as shown by
fluorography and densitometric analysis, directly measured product formation. The

104
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erythrocyte lysis assay widely used to assess HlyA, and indirectly HlyC activity, is
not an appropiate measurement of acyltransferase activity since the stoichiometry of
HlyA toxin lysis remains unkown. Futhermore, lysis was shown not to be a good
measure of HlyA formation because of the dependence of HlyA’s lytic ability upon the
nature o f the HlyA fatty acyl group rather than the quantity of HlyA (discussed below).
The acyltransferase assay also enabled measurement of characteristics which might
independently affect cell membranes and subsequently lysis such as ions, temperature,
etc. on transacylation alone. Developing an HlyC assay system separate from toxin lysis
is important for the study o f the enzyme and its protein substrates. For example, Ca2+ has
been shown to be required for binding the toxin to target cells (30, 31). In contrast, Ca2*
alone among numerous ions investigated inhibited toxin acylation as measured by the
direct assay. Ca2+ inhibition of transacylation likely arose from its effect on proHlyA
conformation (34).
The effects of different fatty acyl groups acylating the toxin on the lytic abilities
of the respective fatty acyl-toxins has not been previously addressed. Different acylACPs varied in their efficacies as substrates for the acyltransferase while the acyl-toxins
exhibited yet a dissimilar ranking of power as lytic agents. Neither the lytic response nor
acyl donor capability of the respective acyl groups was accounted for by increases in
hydrophobicity and membrane affinity associated with the addition o f carbon groups to a
fatty acyl chain (107). Acyl-ACP efficacies declined with increasing chain length; there
was no such trend in the lytic behaviors of HlyA’s bearing different acyl groups. The
introduction of double bonds into an acyl chain decreases its hydrophobicity and its
affinity for membranes (107); no structural generalization was apparent, however,
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regarding acyl group unsaturation and behavior as an acyl-donor. The toxins acylated
with 16 carbon chain length saturated and unsaturated fatty acids were present in
different quantities but produced similar amounts of lysis. In contrast, the toxins acylated
with 18 carbon chain length saturated and unsaturated fatty acids produced similar
amounts of toxin and lysis. Perhaps distinct acyl groups favor separate characteristics
such as toxin aggregatability and different efficiencies of membrane insertion which
contribute to the overall lytic efficacy of a particular toxin. Additionally, the acylation of
a protein may have a significant but as yet undefined effect on its higher order structure.
Although acyl transfer is directly measured in the HlyC assay described herein, whether
one or both of the proHlyA acylation sites was acylated by each of the different acylACP donors is not known. Welch and co-workers have shown that acylation at only one
or the other of the two potential sites has differential effects on hemolytic activity (21,
108). The different lytic efficacies of the HlyA’s bearing different acyl groups could
stem, in part, from unequal acylation of the two potential acylation sites. Since the extent
of lysis depends upon carbon chain length and unsaturation of the acyl-group, lysis
without experimental qualification is not a valid measure of proHlyA activation.
Furthermore, the identity of fatty acyl groups on HlyA produced in vivo are not known.
Acylation of proHlyA to form HlyA was more sensitive to fatty acyl-group
structure than was lysis by the resulting HlyA, but fatty acids or fatty acyl-CoA’s had no
effect on the acyltransferase reaction velocity in contrast to ACPSH which inhibited.
Thus fatty acyl groups per se were not recognized by HlyC while ACPSH was
recognized. Large variations in the Kmvalues o f the various acyl-ACPs pointed to crucial
structural differences among the various acyl-ACPs. These differences could be related
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to different acyl chain lengths fitting an HlyC acyl group binding site for acyl-ACP.
This hypothetical HlyC acyl group binding site likely operated secondary to proteinprotein recognition in view of the fact that fatty acids alone were not inhibitory.
Alternatively, slight but significant conformational variations among acyl-ACP’s cannot
$

be ruled out. NMR studies of ACPSH and octanoyl-ACP suggest that there are not large
structural differences among the acyl-ACPs which served as acyltransferase substrates
(109). Some degree of conformational variation among the acyl-ACPs studied is,
however, established by their different migrations on conformationally sensitive nondenaturing PAGE in the presence of urea (110). The fatty acyl chain strengthens the
native structure in proportion to the carbon chain length (110, 66). A dynamic structure
illustrated as a model involving two conformers provides the best fit o f NM R analysis of
ACP structure (111). With such a structure, different fatty acyl groups may exert distinct
transitions among conformers of the acyl-protein.
Recognition between acyl-ACP and HlyC was underscored by the demonstration
of their binary complex through chemical cross-linking and by the appearance of an acylHlyC intermediate. That the acyl-enzyme intermediate is a step on the main pathway in
the reaction sequence was shown by its disappearance upon proHlyA addition with the
concomitant appearance o f HlyA. It was not a non-reactive, dead-end product; it was a
viable intermediate whose detection depended upon the lack of proHlyA, the acyl
acceptor. Furthermore, the acyl-enzyme intermediate was able to catalyze the reverse
reaction, transferring its acyl group to ACPSH. The formation of heterodimer, acylACP-HlyC, shown by chemical cross-linking corroborated the HPLC demonstration that
monomer was the active form of HlyC. The transfer of the acyl group from the acyl-
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enzyme to proHlyA was apparent, with no evidence o f any heteromolecular
complexes with proHlyA/HlyA. The lack of much variability among Vmu m values
while Km^’s varied extensively suggests that formation of the acyl-enzyme intermediate
varies among acyl-ACP reactants and that acyl transfer from the acyl-enzyme to proHlyA
proceeds at similar rates among acyl-enzyme species. The formation of the acyl-ACPHlyC heterodimer, formation o f an acyl-enzyme intermediate, and the fact that acyl-HlyC
catalyzes the reverse reaction all support a substituted enzyme mechanism for the
acyltransferase reaction.
The kinetic mechanism of HlyC was thoroughly investigated and the results were
consistent with a uni uni iso uni uni ping pong kinetic mechanism where enzyme form F
isomerizes (97). Scheme 1 summarizes the enzyme catalyzed reaction sequence in
Cleland notation (772); F' and F represent the two isomers of the enzyme.

Scheme 1; Kinetic Mechanism o f HlyC, acyl-ACP-proHlyA acyltransferase.
Acyl-ACP

ACPSH

proHlyA

HlyA

E <-* E«acyl-ACP <-> F-acyl <-* F-acyl <-> F-acyl«proHlyA <-> E

Inhibition patterns generated by the products with respect to the different substrates
enabled more exact definition o f the substituted enzyme kinetic mechanism.
Inhibition by the first product, ACPSH, with respect to both myristoyl-ACP and
proHlyA gave primary plots indicative of uncompetitive inhibition; replots of the
l/V IMX',ip values of the family o f plots were, however, hyperbolic. Pure uncompetitive
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inhibition would show a linear replot while the curves continued to move apart as [I]
increased. Instead the inhibition was a mixed-type in which K«, and Vmix changed by the
same factor, but the displacement of the curves approached a limit as [I] increased giving
a hyperbolic replot (86). In this situation, the product inhibitor combines with more than
one enzyme form in alternate reaction sequences resulting in mixed-type inhibition, like
that described generally by Cleland’s rule 3 (113,114) and in more detail by Segel (86).
Scheme 1 shows that the release of the product ACPSH generated an enzyme species
different from that to which myristoyl-ACP bound. The enzyme species to which the
second substrate, proHlyA, bound also differed from the enzyme form that released (and
bound) ACPSH because of the isomerization of the F species o f the enzyme prior to
binding proHlyA. Inhibition by product under these circumstances would be expected to
be mixed-type (1 IS).
Inhibition by the second product, HlyA unambiguously showed competitive
inhibition in both primary plots with either myristoyl-ACP or proHlyA as varied
substrates at unsaturating levels o f the other. Replots of the data from the two separate
primary plots of HlyA inhibition were, however, quite dissimilar indicating different
mechanisms of inhibition by HlyA for each of the two substrates. The tendency of HlyA
to aggregate (76) placed an upper limit on the concentrations that could be examined in
the HlyC assay. With respect to myristoyl-ACP, HlyA was a parabolic or two site
competitive inhibitor, the sites are separate and independent o f one another (87). Replots
to calculate K; for a two site competitive inhibitor were not linear indicating that there
were more than two independent inhibitor binding sites (87). Scheme 1 demonstrates that
myristoyl-ACP and the product HlyA bind to the same species o f enzyme thus predicting

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

a competitive type of inhibition in accordance with Cleland’s rules that also predict

no

the observed parabolic effect on replots upon binding o f multiple inhibitor molecules
U I3 ).
HlyA inhibition with respect to proHlyA, although showing primary plots
diagnostic o f competitive inhibition, gave rise to replots quite different from parabolic or
linear competitive inhibition. Both the hyperbolic replot o f Kffl*pp/V inax*n> against [I] and
the leveling-off o f v versus [I] curves indicated partial competitive inhibition (Figures 19
(inset) and 20B). Scheme 1, however, shows that, in contradiction to competitive
inhibition, HlyA and proHlyA bind to different enzyme forms ( / 13). Segel (90)
describes multiple situations which give rise to mixed-type inhibition. Included is a
circumstance that resembles partial competitive inhibition, but it is not. It is really a form
of mixed-type inhibition, and it is a specific example o f a Cleland rule 3 situation where a
compound reacts with two different enzyme forms (sites) causing different effects which
result in hyperbolic replots (113). According to the model presented by Segel (116)
which is diagramed in Figure 33, the mixed-type inhibition in this instance arises from
the hypothetical existence of two separate types of sites for inhibitor binding which are
mutually exclusive. The model involves the interplay o f two separate and differently
behaving inhibitor binding sites and yet another binding site, the substrate binding site
(Figure 33, E). Neither inhibitor binding site is the catalytic site (substrate binding site).
There are, however, electronic or conformational responses within the enzyme upon
occupation o f either inhibitor binding site by inhibitor which cause the following
behaviors in the remaining two sites, the alternate inhibitor binding site and the substrate
binding site: One inhibitor binding site is a noninhibitory site that, when occupied,
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noninhibitory site

catalytic site

inhibitory site

Figure 33: Mixed-type inhibition model of binding sites, possible occupancies, and
resulting enzyme forms in HlyA product inhibition with respect to proHlyA.
Abbreviations and symbols are as follows: I, inhibitor; S, substrate; El41, inhibitory
enzyme-inhibitor complex; IE, noninhibitory enzyme-inhibitory complex, ES, enzymesubstrate complex; IES, noninhibitory inhibitor-enzyme-substrate complex. Model
adopted from Segel (116).
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distorts the second inhibitor binding site and prevents its binding of inhibitor, while
substrate binding (and subsequent activity) is unimpaired (Figure 33, IE and IES). Thus
inhibition can only be partial because all inhibitor binding does not result in inhibition.
The second inhibitor binding site, when occupied, causes distortions of both the
noninhibitory inhibitor binding site and the substrate binding site (Figure 33, E l*). It
prevents substrate from binding to the catalytic site (pure competitive action). The model
gives rise to a mixed-type inhibition because in one instance inhibitor and substrate (IES)
can bind simultaneously to the enzyme while in another instance only inhibitor (E l*) or
substrate (ES) can bind to the enzyme. This mixed-type inhibition appears as partial
competitive inhibition and cannot be distinguished by kinetics from a single-site model of
partial competitive inhibition.
The steady state kinetics, the demonstration of a reactive acyl-enzyme
intermediate, and the demonstration of the reversible first half reaction all supported a
ping pong kinetic mechanism for HlyC. Distinctions among several different types of bi
bi ping pong mechanisms were made by analyses of the product inhibition patterns with
respect to the various substrates. The results of these studies o f the internal protein
acyltransferase reaction are compatible with a uni uni iso uni uni ping pong kinetic
mechanism where enzyme form F isomerized.
Once the kinetic mechanism was defined, efforts were turned to elucidating the
chemical mechanism o f the enzyme. Chemical modification o f HlyC suggested the
possibility of histidines, tyrosines, and arginine residues being involved in HlyC catalysis
while ruling out the possibility of any crucial serines, cysteines, and, indirectly, lysine
residues. Overall, data from chemical modification and site-directed mutagenesis
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experiments agreed very well. For example, the CS7A mutant possessed wild-type
acyltransferase function, and HlyC was insensitive to sulfhydryl modifying reagents.
Also, treatment of the enzyme with TNM at pH 6.0 did not inactivate the enzyme,
conditions that result in thiol oxidation (777). Mutation experiments revealed that Ser 20
and 76 were necessary for wild-type function. This finding did not contradict the
chemical modification data showing no inhibition of acyltransferase activity by PMSF
and AEBSF, since PMSF and AEBSF tend to react with unusually reactive serines and in
some cases do not react with serines known to function as active site nucleophiles. For
example, the malonyl-/acetyltransferase has an active site serine contained within the
GXSXG motif characteristic of many serine active site esterases (775), but the enzyme is
not inhibited by PMSF.
HlyC was very sensitive to DEPC modification and evidence was presented to
suggest specific histidine modification. Inactivation of enzyme was enhanced at pH 6.0
which suggested histidine modification, since DEPC prefers unprotonated nucleophiles
(79). Further evidence included the reactivation of DEPC modified HlyC by
hydroxylamine treatment and the spectral evidence of N-carbethoxyhistidine formation
with lack of ethoxyformylation o f tyrosine. The importance of the modified histidine(s)
was demonstrated by substrate protection experiments indicating the modified residue is
located within or near the active site of HlyC. The fact that acyl-ACP protected HlyC
from DEPC modification; whereas, ACPSH offered no protection could be attributed to a
histidine lying within an acyl group binding site in the enzyme. Also, according to the
predicted uni uni iso uni uni ping pong kinetic mechanism of HlyC, ACPSH binds to a
different form of the acyltransferase than acyl-ACP; therefore, lack o f protection could

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

114
simply be lack of protein-protein interaction of ACPSH with a specific form o f the
enzyme.
Although DEPC could modify any of the 6 histidines of HlyC, His 23 was chosen
for site-directed mutagenesis experiments because of its conservation among the RTX
toxin acyltransferases. Mutation o f conserved His 23 to alanine corroborated the
importance o f histidine modification by DEPC. In addition to H23A, the H23S and
H23C mutants were totally inactive. While serine and cysteine residues could function as
nucleophiles during acyl-enzyme intermediate formation, they typically do not function
in acid-base catalysis. Lack of activity for the H23S and H23C mutants does not rule out
the possibility o f His 23 functioning as the active site nucleophile since conversion of His
23 to a serine and cysteine residue could disturb the position and orientation of the active
site. In some cases, substitution o f the active site nucleophile with a second nucleophilic
side chain is successiveful, but other times only minimal activity is retained. For
example, the plant acyl-ACP thioesterase retains >60% activity upon mutation of the
nucleophilic cysteine to a serine residue {119), whereas, replacement o f the active serine
o f the malony-/acetyltransferase with cysteine results in retention of ~l% activity (118).
Such a small retention of activity for H23C or H23S would not be detectable using the
current HlyC assay system.
Inactivation o f HlyC by TN M suggested an important tyrosine(s) and this was
further evident by a pH dependency o f TNM modification at pH 8.0, as well as spectral
data showing formation of 3-nitrotyrosine. Chemical data suggesting a reduction in
acyltransferase activity due to tyrosine modification was confirmed by mutating
conserved Tyr 70 and ISO to glycines since mutational studies showed both residues were
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critical for wild-type enzyme function. HlyC contains 7 tyrosines, 2 being fully
conserved, and 3 more conserved for hydrophobicity. TNM could potentially modify all
of HlyC’s tyrosines, but only the function of Tyr 70 and 150 were addressed in the sitedirected mutagenesis studies presented here since this work focused on conserved
residues among the different RTX toxin acyltransferases. Substitution of a tyrosine to a
glycine residue results in an amino acid change with the greatest decrease in
hydrophobicity, but still allows for flexibility in protein secondary structure (120).
Changing either Tyr 70 or Tyr 150 to a glycine residue did not predict changes in HlyC
secondary structure. Comparison of quickly diluted and refolded HlyCs allowed further
characterization of mutant enzymes helping to suggest roles for various residues. The
20% increase upon slowly refolding Y150G most likely results from conformational
changes, suggesting Tyr 150 has a role in protein conformation and/or stabilization.
Decreases in activity observed with HlyC mutants Y70G and Y150G could easily
be recovered by replacing the glycine with a phenylalanine restoring hydrophobicity and
showing the lack of need for the -O H group. That an important tyrosine whose -O H
group was not essential was also shown by chemical modification experiments, since
HlyC acyltransferase activity was insensitive to acetylation o f the tyrosyl -O H by NAI
and acylation by DEPC (pH 8.0), but inactivated by TNM nitration of the tyrosyl
phenolic ring (pH 8.0). As with DEPC inactivation of HlyC, the importance of a tyrosine
residue(s) was underscored by protection experiments from TNM. Inactivation of
enzyme by TN M in the presence of acyl-ACP was unsuccessful but in the presence of
ACPSH inactivation proceeded as ususal. Perhaps one o f the conserved tyrosine residues
is necessary for providing a hydrophobic environment within an acyl group binding site
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in HlyC for the acyl-ACP substrate. This may explain chemical cross-linking data
since Y70G and Y150G formed low levels of heterodimer suggesting a role in substrate
recognition. Also, mutation of the conserved tyrosines could lead to an overall
conformational change decreasing acyl-ACP substrate recognition unrelated to acyl
group recognition. It would be of interest to determine if ACPSH cross-links to a greater
degree to Y70G and Y150G HlyC mutants, as compared to acyl-ACP.
HlyC contains 6 arginines with 2 conserved among the 13 acyltransferases. An
important arginine(s) was suggested by PG modification and confirmed by mutation of
conserved positively charged Arg 24 and Arg 87 to alanines. Like the Y1S0G mutant,
R87A showed an increase in activity upon slow renaturation, in this case an increase of
-70% as compared to HlyC refolded by quick dilution. This data implied that Arg 87 is
important in protein conformation. Reduction in activity seen with the R24A and R87A
mutations could be a result in the removal of positive charge or possibly the change in
residue size. Further mutations will be necessary to determine the role of these conserved
residues. Acyl-ACP protected HlyC from PG modification, but to a lesser extent than
found in TNM and DEPC modification experiments. Also for the first time ACPSH
offered marginal protection. Taken together the protection experiments indicate that the
modified arginine(s) is less likely to be influenced by the acyl chain of the acyl-ACP
substrate and therefore less likely to be involved at the catalytic site. It seems that Arg 24
and 87 are most likely involved in a protein structural role rather than in the catalysis.
Perhaps the positively charged residues participate in binding to the negatively charged
acyl-ACP substrate, since ACPSH can protect HlyC from PG modification, albeit at
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lower levels. This is partially supported by chemical cross-linking data since R24A
produces less heterodimer compared to wild-type HlyC control.
Mutation o f the only conserved acidic residues E67 and D86 to alanines gave
mixed results. E67A functioned at wild-type levels, and D86A showed a decrease in
activity. Finally conserved glycines 11 and 85 were mutated to alanines with both
mutations leading to non-functional HlyCs, most likely arising from changes in protein
conformation since glycine residues are typically not involved at the catalytic site.
Whether or not a single-site amino acid change within HlyC could change the acyl group
specificity of the acyl-ACP substrate was not addressed. Although this seems unlikely,
since myristoyl-ACP was used in comparing mutant and native enzyme function, a
change in the acyl chain specificity for a mutant enzyme as compared to the wild-type
control would lead to misinterpretation of the results. Such an instance has been reported
in which mutating a single amino acid of the lysophosphatidate acyltransferase (LP AT)
resulted in changes in acyl-CoA substrate specificity (121).
Cross-linking experiments and acyl-enzyme intermediate formation by mutant
HlyCs proved to be valuable experiments for suggesting roles of amino acid residues in
the acyltransferase mechanism. For example, the H23A, H23S, and H23C mutants were
incapable o f forming acyl-enzyme intermediate, but all cross-linked at wild-type levels
with acyl-ACP. These data imply His 23 is not necessary for acyl-ACP substrate
binding, but critical for the formation of acyl-HlyC, the first half of the proHlyA
acylation reaction. All single site mutations gave rise to HlyCs that cross-linked to acylACP to some extent except for one, G85 A. No mutants formed acyl-enzyme
intermediate without cross-linking to acyl-ACP, suggesting that heterodimer formation is
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a step along the pathway to acyl-enzyme formation. Upon examining acylintermediate formation for the various HlyCs, it was found that several enzymes
produced an acyl-HlyC dimer, something not seen with the wild-type acyltransferase.
Determination of the kinetic parameters for the mutant enzymes showed little
difference from the wild-type acyltransferase. There were, however, significant changes
in VmM*"’ values for both acyl-ACP and proHlyA substrates when the S20A or Y150G
mutants were the source of enzyme, implying that Ser 20 and Tyr ISO are involved in the
the acyl transfer reaction. This, however, does not rule out a conformational role for Ser
20 and Tyr ISO.
With the data from chemical modification and site-directed mutagenesis
experiments one can conclude that HlyC contains several residues that are critical for
acyltransferase function, an essential histidine; His 23, an essential tyrosine; Tyr 70, and
two essential glycines; Gly 11 and 8S. The remainder of the mutations, while in some
cases significantly affecting enzyme function, were tolerable since HlyC was not
completely inactivated. O f the residues listed above only His 23 and Tyr 70 could have
an acyl group covalently attached to their respective side chains. Since replacement of
the two conserved tyrosines with phenylalanines restored enzyme activity, Tyr 70 cannot
be the site of HlyC acylation in acyl-intermediate formation. This leaves only His 23.
As discusssed earlier, based upon protein sequence comparison data, HlyC is a
unique acyltransferase. This follows with the work presented here since HlyC appears to
contain no essential cysteines or serines needed for acyl transfer, which is not the case for
enzymes typically involved in these sort of reactions. For many acyltransferases,
esterases, lipases, and proteinases a histidine residue functions in an acid-base role with a
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second amino acid, a serine or cysteine, functioning as the nucleophile. Upon sitedirected mutagenesis o f these histidine residues, the enzymes become very inefficient,
but, generally, complete loss of activity is seen only when the serine or cysteine residues
that function as nucleophiles in the chemical mechanism are mutated {122). The HlyC
acyltransferase is notable in that it loses all detectable activity upon mutation of the single
conserved histidine residue, but the enzyme retains activity, although impaired in some
instances, upon mutation of conserved serines or cysteine residues.
HlyC contains I cysteine and 11 serines. Since the CS7A mutant retained native
acyltransferase activity this removes the possibility of an -SH group functioning as a
nucleophile. Although all of the serine residues were not mutated, with the chemical
modification and mutagenesis data presented here it would seem unlikely that HlyC
contains an active site serine since the remaining 8 serines are not conserved among the
RTX toxin acyltransferases. To date, there have been no enzymes shown to possess a
histidine functioning as the active site nucleophile giving rise to an acyl-imidazole
intermediate. However, a histidine residue has been shown to act as a nucleophile
forming an acyl-antibody intermediate in a reaction catalyzed by an antibody {123) and
histidine 1106 of the C4B isotype o f human complement forms an acyl-imidazole
intermediate after attacking an internal thioester located within the protein {124,125).
With the evidence presented above it is feasible that His 23 functions as a nucleophile in
the transfer of acyl groups from acyl-ACP to proHlyA. In order to clarify further the
chemical mechanism of HlyC, additional studies will be necessary.
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